| Min Pa: | Min Pa(max): | Activity's type: |
| Ext | Pa | Pi | Pmax | Activity | Other Results | ID Pa_max |
|---|---|---|---|---|---|---|
| 0.851 | 0.002 | 0.851 | Alcohol oxidase inhibitor | 0.224 0.005 DBMET02629 0.158 0.009 DBMET02630 0.122 0.014 DBMET02631 0.121 0.014 DBMET02632 0.061 0.035 DBMET02633 0.126 0.013 DBMET02634 | ||
| 0.779 | 0.002 | 0.779 | Porphobilinogen synthase inhibitor | 0.354 0.004 DBMET02629 0.482 0.004 DBMET02630 0.156 0.019 DBMET02631 0.194 0.013 DBMET02632 0.118 0.029 DBMET02633 0.167 0.017 DBMET02634 | ||
| 0.724 | 0.004 | 0.724 | 5 Hydroxytryptamine release inhibitor | 0.577 0.014 DBMET02629 0.46 0.047 DBMET02630 0.389 0.085 DBMET02631 0.416 0.068 DBMET02632 0.359 0.108 DBMET02633 0.369 0.1 DBMET02634 | ||
| 0.702 | 0.005 | 0.702 | Histamine release inhibitor | 0.477 0.037 DBMET02629 0.514 0.024 DBMET02630 0.227 0.174 DBMET02631 0.473 0.039 DBMET02632 0.329 0.109 DBMET02633 0.339 0.105 DBMET02634 | ||
| 0.696 | 0.008 | 0.696 | Cholesterol antagonist | 0.327 0.075 DBMET02629 0.507 0.031 DBMET02630 0.237 0.135 DBMET02631 0.343 0.067 DBMET02632 | ||
| 0.634 | 0.005 | 0.634 | Superoxide dismutase inhibitor | 0.44 0.02 DBMET02629 0.481 0.015 DBMET02630 0.24 0.081 DBMET02631 0.256 0.071 DBMET02632 0.238 0.082 DBMET02633 0.184 0.137 DBMET02634 | ||
| 0.627 | 0.004 | 0.627 | Alpha-N-acetylglucosaminidase inhibitor | 0.213 0.03 DBMET02629 0.331 0.013 DBMET02630 0.165 0.047 DBMET02631 0.3 0.016 DBMET02632 0.108 0.09 DBMET02633 0.139 0.062 DBMET02634 | ||
| 0.621 | 0.005 | 0.621 | Ca2+/calmodulin-dependent protein kinase kinase A inhibitor | 0.578 0.01 DBMET02629 0.507 0.03 DBMET02630 0.407 0.094 DBMET02631 0.467 0.051 DBMET02632 0.398 0.102 DBMET02633 0.42 0.083 DBMET02634 | ||
| 0.627 | 0.013 | 0.627 | Vasodilator, peripheral | 0.226 0.148 DBMET02629 0.277 0.11 DBMET02630 0.283 0.106 DBMET02631 0.326 0.084 DBMET02632 | ||
| 0.602 | 0.003 | 0.602 | GABA C receptor agonist | 0.32 0.008 DBMET02629 0.372 0.006 DBMET02630 0.221 0.017 DBMET02631 0.24 0.014 DBMET02632 0.165 0.029 DBMET02633 0.169 0.028 DBMET02634 | ||
| 0.563 | 0.024 | 0.563 | Aldehyde oxidase inhibitor | 0.176 0.119 DBMET02629 0.238 0.087 DBMET02630 0.301 0.066 DBMET02632 0.168 0.124 DBMET02633 0.16 0.13 DBMET02634 | ||
| 0.538 | 0.017 | 0.576 | GABA C receptor rho-3 antagonist | 0.55 0.014 DBMET02629 0.576 0.01 DBMET02630 0.384 0.069 DBMET02631 0.564 0.012 DBMET02632 0.522 0.02 DBMET02633 0.511 0.023 DBMET02634 | DBMET02630 | |
| 0.526 | 0.008 | 0.567 | Peroxidase inhibitor | 0.491 0.01 DBMET02629 0.567 0.005 DBMET02630 0.294 0.038 DBMET02631 0.297 0.038 DBMET02632 0.182 0.064 DBMET02633 0.374 0.024 DBMET02634 | DBMET02630 | |
| 0.53 | 0.042 | 0.53 | Cyclophilin D inhibitor | 0.37 0.109 DBMET02630 0.267 0.194 DBMET02631 0.308 0.156 DBMET02632 | ||
| 0.455 | 0.006 | 0.455 | NOS3 expression enhancer | 0.175 0.053 DBMET02629 0.129 0.099 DBMET02630 0.188 0.046 DBMET02632 | ||
| 0.441 | 0.002 | 0.441 | Aconitate hydratase inhibitor | 0.128 0.005 DBMET02629 0.158 0.004 DBMET02630 0.076 0.015 DBMET02631 0.106 0.007 DBMET02632 0.051 0.037 DBMET02634 | ||
| 0.401 | 0.004 | 0.401 | Ferrochelatase inhibitor | 0.236 0.015 DBMET02629 0.192 0.024 DBMET02630 0.147 0.039 DBMET02631 0.283 0.009 DBMET02632 0.153 0.036 DBMET02633 0.372 0.004 DBMET02634 | ||
| 0.404 | 0.013 | 0.404 | 5 Hydroxytryptamine uptake stimulant | 0.347 0.026 DBMET02629 0.262 0.07 DBMET02630 0.26 0.072 DBMET02631 0.388 0.016 DBMET02632 0.313 0.039 DBMET02633 0.314 0.038 DBMET02634 | ||
| 0.43 | 0.042 | 0.481 | Antithrombotic | 0.297 0.09 DBMET02629 0.481 0.032 DBMET02630 0.271 0.11 DBMET02631 0.241 0.133 DBMET02632 0.2 0.177 DBMET02634 | DBMET02630 | |
| 0.392 | 0.025 | 0.419 | Vasodilator | 0.186 0.116 DBMET02630 0.419 0.02 DBMET02631 0.243 0.073 DBMET02632 | DBMET02631 | |
| 0.391 | 0.028 | 0.391 | Calcium channel activator | 0.326 0.068 DBMET02629 0.237 0.163 DBMET02630 0.232 0.169 DBMET02631 0.305 0.087 DBMET02632 | ||
| 0.395 | 0.037 | 0.395 | Vasodilator, coronary | 0.289 0.096 DBMET02629 0.324 0.07 DBMET02630 0.292 0.094 DBMET02631 0.279 0.106 DBMET02632 | ||
| 0.358 | 0.003 | 0.358 | Keratolytic | 0.146 0.015 DBMET02629 0.15 0.014 DBMET02630 0.099 0.031 DBMET02631 0.085 0.042 DBMET02632 | ||
| 0.353 | 0.005 | 0.516 | Nitric-oxide synthase stimulant | 0.442 0.003 DBMET02629 0.494 0.002 DBMET02630 0.516 0.002 DBMET02631 0.218 0.062 DBMET02632 0.194 0.099 DBMET02633 0.243 0.037 DBMET02634 | DBMET02631 | |
| 0.347 | 0.003 | 0.347 | Electrolyte absorption antagonist | 0.13 0.029 DBMET02629 0.172 0.013 DBMET02630 0.191 0.009 DBMET02632 0.145 0.021 DBMET02634 | ||
| 0.344 | 0.005 | 0.344 | 3C-like protease (Human coronavirus) inhibitor | 0.306 0.01 DBMET02629 0.2 0.052 DBMET02630 0.169 0.075 DBMET02631 0.223 0.04 DBMET02632 0.144 0.112 DBMET02633 0.158 0.089 DBMET02634 | ||
| 0.367 | 0.034 | 0.367 | Hypoglycemic | 0.214 0.1 DBMET02630 0.286 0.058 DBMET02632 | ||
| 0.335 | 0.005 | 0.335 | Histidine decarboxylase inhibitor | 0.14 0.021 DBMET02629 0.253 0.009 DBMET02630 0.075 0.046 DBMET02631 0.086 0.039 DBMET02632 0.069 0.051 DBMET02633 0.142 0.021 DBMET02634 | ||
| 0.325 | 0.004 | 0.325 | Phenylalanine 4-hydroxylase inhibitor | 0.162 0.01 DBMET02629 0.221 0.005 DBMET02630 0.08 0.038 DBMET02631 0.09 0.031 DBMET02632 0.06 0.058 DBMET02634 | ||
| 0.347 | 0.026 | 0.347 | Cyclic AMP phosphodiesterase inhibitor | 0.175 0.116 DBMET02629 0.212 0.085 DBMET02632 0.156 0.141 DBMET02634 | ||
| 0.328 | 0.009 | 0.328 | UDP-glucose 4-epimerase inhibitor | 0.117 0.045 DBMET02629 0.089 0.074 DBMET02630 0.11 0.051 DBMET02631 0.15 0.029 DBMET02632 0.09 0.073 DBMET02633 0.146 0.03 DBMET02634 | ||
| 0.349 | 0.03 | 0.349 | DNA synthesis inhibitor | 0.217 0.098 DBMET02629 0.251 0.065 DBMET02630 0.248 0.068 DBMET02631 0.278 0.052 DBMET02632 0.25 0.066 DBMET02633 0.232 0.081 DBMET02634 | ||
| 0.413 | 0.103 | 0.435 | Caspase 9 stimulant | 0.338 0.155 DBMET02629 0.323 0.169 DBMET02630 0.435 0.091 DBMET02632 0.282 0.214 DBMET02634 | DBMET02632 | |
| 0.313 | 0.009 | 0.313 | Succinate dehydrogenase inhibitor | 0.189 0.058 DBMET02629 0.206 0.044 DBMET02630 0.175 0.074 DBMET02631 0.208 0.042 DBMET02632 0.168 0.084 DBMET02633 0.196 0.052 DBMET02634 | ||
| 0.338 | 0.039 | 0.354 | Insulysin inhibitor | 0.328 0.043 DBMET02629 0.354 0.033 DBMET02630 0.351 0.034 DBMET02631 0.252 0.095 DBMET02632 0.24 0.106 DBMET02633 0.332 0.041 DBMET02634 | DBMET02630 | |
| 0.308 | 0.009 | 0.308 | Cystathionine beta-synthase inhibitor | 0.159 0.037 DBMET02629 0.124 0.055 DBMET02630 0.198 0.025 DBMET02632 0.129 0.052 DBMET02633 0.15 0.04 DBMET02634 | ||
| 0.388 | 0.089 | 0.388 | Calcium channel L-type activator | 0.262 0.193 DBMET02629 | ||
| 0.307 | 0.011 | 0.307 | Aldehyde dehydrogenase inhibitor | 0.228 0.022 DBMET02629 0.303 0.011 DBMET02630 0.115 0.077 DBMET02631 0.132 0.06 DBMET02632 0.102 0.094 DBMET02633 0.241 0.019 DBMET02634 | ||
| 0.37 | 0.078 | 0.502 | MAP kinase kinase 6 inhibitor | 0.502 0.018 DBMET02629 0.451 0.034 DBMET02631 0.25 0.19 DBMET02633 0.266 0.17 DBMET02634 | DBMET02629 | |
| 0.295 | 0.005 | 0.295 | Triose-phosphate isomerase inhibitor | 0.112 0.037 DBMET02629 0.11 0.039 DBMET02630 0.107 0.041 DBMET02631 0.124 0.03 DBMET02632 0.083 0.071 DBMET02633 0.128 0.028 DBMET02634 | ||
| 0.289 | 0.003 | 0.289 | Biliverdin reductase inhibitor | 0.266 0.004 DBMET02629 0.144 0.01 DBMET02630 0.234 0.004 DBMET02631 0.117 0.014 DBMET02632 0.089 0.022 DBMET02633 0.283 0.004 DBMET02634 | ||
| 0.286 | 0.003 | 0.286 | Glutamate (mGluR4) antagonist | 0.092 0.006 DBMET02629 0.076 0.009 DBMET02630 0.047 0.025 DBMET02631 0.063 0.013 DBMET02632 | ||
| 0.369 | 0.092 | 0.416 | Antibacterial | 0.301 0.135 DBMET02631 0.404 0.075 DBMET02632 0.416 0.07 DBMET02633 0.249 0.177 DBMET02634 | DBMET02633 | |
| 0.306 | 0.03 | 0.306 | RNA-directed DNA polymerase inhibitor | 0.242 0.054 DBMET02629 0.185 0.123 DBMET02631 0.305 0.031 DBMET02632 0.245 0.052 DBMET02633 0.204 0.094 DBMET02634 | ||
| 0.282 | 0.007 | 0.282 | UDP-N-acetylglucosamine 1-carboxyvinyltransferase inhibitor | 0.105 0.049 DBMET02629 0.091 0.065 DBMET02630 0.102 0.052 DBMET02631 0.114 0.043 DBMET02632 0.137 0.031 DBMET02634 | ||
| 0.283 | 0.012 | 0.38 | Chelator | 0.38 0.006 DBMET02630 0.204 0.024 DBMET02632 | DBMET02630 | |
| 0.323 | 0.059 | 0.45 | Sodium/bile acid cotransporter inhibitor | 0.45 0.007 DBMET02630 0.216 0.166 DBMET02632 | DBMET02630 | |
| 0.277 | 0.014 | 0.277 | Cholesterol synthesis inhibitor | 0.143 0.048 DBMET02630 0.104 0.082 DBMET02632 | ||
| 0.267 | 0.006 | 0.267 | Uric acid excretion stimulant | |||
| 0.271 | 0.014 | 0.271 | Hexokinase inhibitor | 0.163 0.064 DBMET02629 | ||
| 0.259 | 0.003 | 0.259 | Glutamate (mGluR group III) antagonist | 0.081 0.007 DBMET02629 0.053 0.018 DBMET02630 0.043 0.033 DBMET02631 0.085 0.007 DBMET02632 0.047 0.025 DBMET02634 | ||
| 0.293 | 0.038 | 0.318 | Gastrin inhibitor | 0.19 0.165 DBMET02629 0.318 0.022 DBMET02630 0.244 0.086 DBMET02632 0.194 0.158 DBMET02634 | DBMET02630 | |
| 0.275 | 0.025 | 0.304 | I kappa B kinase epsilon inhibitor | 0.304 0.013 DBMET02629 0.198 0.072 DBMET02630 0.168 0.101 DBMET02631 0.155 0.114 DBMET02633 0.2 0.071 DBMET02634 | DBMET02629 | |
| 0.254 | 0.004 | 0.267 | GABA C receptor rho-1 antagonist | 0.267 0.004 DBMET02629 0.222 0.005 DBMET02630 0.17 0.014 DBMET02631 0.152 0.02 DBMET02632 0.191 0.009 DBMET02633 0.2 0.008 DBMET02634 | DBMET02629 | |
| 0.257 | 0.009 | 0.257 | Adenylate kinase inhibitor | 0.129 0.036 DBMET02629 0.151 0.026 DBMET02630 0.113 0.05 DBMET02631 0.129 0.037 DBMET02632 0.096 0.075 DBMET02633 0.143 0.029 DBMET02634 | ||
| 0.39 | 0.145 | 0.466 | Antiinflammatory | 0.353 0.17 DBMET02631 0.327 0.191 DBMET02632 0.466 0.103 DBMET02634 | DBMET02634 | |
| 0.253 | 0.011 | 0.259 | GABA C receptor rho-2 antagonist | 0.221 0.019 DBMET02629 0.259 0.01 DBMET02630 0.142 0.084 DBMET02631 0.236 0.015 DBMET02632 0.183 0.04 DBMET02633 0.184 0.039 DBMET02634 | DBMET02630 | |
| 0.267 | 0.025 | 0.267 | Interferon gamma antagonist | 0.15 0.077 DBMET02629 0.127 0.118 DBMET02630 0.13 0.111 DBMET02632 | ||
| 0.263 | 0.021 | 0.387 | MAP kinase kinase 3 inhibitor | 0.387 0.003 DBMET02629 0.24 0.042 DBMET02630 0.292 0.009 DBMET02631 0.274 0.015 DBMET02633 0.277 0.014 DBMET02634 | DBMET02629 | |
| 0.257 | 0.015 | 0.257 | Protein kinase (CK2) alpha inhibitor | 0.139 0.049 DBMET02629 | ||
| 0.304 | 0.068 | 0.304 | Spasmolytic | 0.201 0.119 DBMET02629 0.172 0.144 DBMET02630 0.245 0.093 DBMET02632 | ||
| 0.251 | 0.016 | 0.296 | Cell wall synthesis inhibitor | 0.178 0.041 DBMET02629 0.164 0.053 DBMET02630 0.132 0.084 DBMET02631 0.296 0.01 DBMET02632 0.242 0.018 DBMET02633 0.185 0.037 DBMET02634 | DBMET02632 | |
| 0.243 | 0.008 | 0.243 | Alcohol dehydrogenase inhibitor | 0.217 0.01 DBMET02629 0.18 0.015 DBMET02630 0.12 0.035 DBMET02631 0.124 0.032 DBMET02632 0.119 0.035 DBMET02633 0.2 0.012 DBMET02634 | ||
| 0.312 | 0.078 | 0.633 | Apoptosis antagonist | 0.303 0.084 DBMET02630 0.633 0.006 DBMET02632 0.368 0.048 DBMET02633 | DBMET02632 | |
| 0.24 | 0.007 | 0.268 | GABA C receptor antagonist | 0.268 0.005 DBMET02629 0.201 0.013 DBMET02630 0.169 0.021 DBMET02631 0.14 0.036 DBMET02632 0.169 0.021 DBMET02633 0.184 0.017 DBMET02634 | DBMET02629 | |
| 0.241 | 0.008 | 0.241 | Glutamate dehydrogenase inhibitor | 0.159 0.014 DBMET02629 0.144 0.017 DBMET02630 0.118 0.023 DBMET02631 0.093 0.035 DBMET02632 0.093 0.035 DBMET02633 0.164 0.014 DBMET02634 | ||
| 0.234 | 0.005 | 0.234 | Glutamate decarboxylase inhibitor | 0.109 0.025 DBMET02629 0.153 0.013 DBMET02630 0.078 0.046 DBMET02631 0.093 0.034 DBMET02632 0.07 0.054 DBMET02633 0.105 0.027 DBMET02634 | ||
| 0.257 | 0.03 | 0.257 | Insulin sensitizer | 0.151 0.132 DBMET02629 0.233 0.045 DBMET02630 0.182 0.093 DBMET02632 | ||
| 0.237 | 0.013 | 0.237 | Protein kinase (CK2) inhibitor | 0.113 0.053 DBMET02629 | ||
| 0.228 | 0.005 | 0.242 | CYP2A6 inhibitor | 0.242 0.005 DBMET02629 0.078 0.05 DBMET02630 0.073 0.056 DBMET02631 0.185 0.009 DBMET02632 0.105 0.033 DBMET02633 0.073 0.055 DBMET02634 | DBMET02629 | |
| 0.229 | 0.009 | 0.229 | NADH dehydrogenase inhibitor | 0.103 0.041 DBMET02629 0.122 0.027 DBMET02630 0.111 0.034 DBMET02632 0.113 0.033 DBMET02634 | ||
| 0.25 | 0.029 | 0.404 | Cytidine deaminase inhibitor | 0.157 0.07 DBMET02629 0.121 0.099 DBMET02630 0.404 0.01 DBMET02632 0.225 0.037 DBMET02633 0.193 0.051 DBMET02634 | DBMET02632 | |
| 0.235 | 0.016 | 0.235 | Mannose-6-phosphate isomerase inhibitor | 0.17 0.049 DBMET02629 0.121 0.099 DBMET02630 0.127 0.089 DBMET02632 | ||
| 0.263 | 0.045 | 0.263 | Anesthetic general | 0.149 0.115 DBMET02629 0.184 0.084 DBMET02632 | ||
| 0.256 | 0.04 | 0.296 | Glyceraldehyde-3-phosphate dehydrogenase inhibitor | 0.22 0.058 DBMET02629 0.174 0.101 DBMET02630 0.296 0.025 DBMET02631 0.223 0.056 DBMET02632 0.246 0.044 DBMET02633 0.182 0.09 DBMET02634 | DBMET02631 | |
| 0.223 | 0.008 | 0.223 | ABCA1 expression enhancer | 0.108 0.041 DBMET02630 | ||
| 0.285 | 0.073 | 0.296 | Hypoxia-inducible factor 1 alpha inhibitor | 0.296 0.068 DBMET02630 0.18 0.178 DBMET02632 | DBMET02630 | |
| 0.214 | 0.003 | 0.214 | Nicotinic acid receptor agonist | 0.104 0.005 DBMET02632 | ||
| 0.214 | 0.004 | 0.214 | Nicotinic acid receptor 2 agonist | 0.096 0.006 DBMET02632 | ||
| 0.213 | 0.004 | 0.213 | Xanthine dehydrogenase inhibitor | 0.056 0.041 DBMET02629 0.052 0.045 DBMET02630 0.056 0.041 DBMET02632 | ||
| 0.272 | 0.064 | 0.285 | Interleukin agonist | 0.269 0.065 DBMET02629 0.202 0.118 DBMET02630 0.235 0.09 DBMET02631 0.211 0.111 DBMET02632 0.285 0.056 DBMET02633 0.242 0.085 DBMET02634 | DBMET02633 | |
| 0.218 | 0.012 | 0.288 | Ca2+/calmodulin-dependent protein kinase kinase B inhibitor | 0.288 0.004 DBMET02629 0.203 0.017 DBMET02631 0.201 0.018 DBMET02633 0.212 0.013 DBMET02634 | DBMET02629 | |
| 0.225 | 0.02 | 0.225 | Glutamate receptor antagonist | 0.123 0.071 DBMET02629 0.143 0.056 DBMET02631 | ||
| 0.215 | 0.01 | 0.215 | Phosphofructokinase-1 inhibitor | 0.093 0.034 DBMET02629 0.084 0.039 DBMET02630 0.064 0.052 DBMET02631 0.087 0.037 DBMET02632 0.063 0.053 DBMET02633 | ||
| 0.266 | 0.061 | 0.354 | Dual specificity tyrosine-phosphorylation regulated kinase 1A inhibitor | 0.354 0.035 DBMET02629 | DBMET02629 | |
| 0.261 | 0.058 | 0.321 | Tyrosine 3 hydroxylase inhibitor | 0.26 0.059 DBMET02629 0.321 0.024 DBMET02630 0.25 0.068 DBMET02631 0.282 0.043 DBMET02632 0.273 0.049 DBMET02633 0.263 0.057 DBMET02634 | DBMET02630 | |
| 0.264 | 0.061 | 0.264 | Hypolipemic | 0.159 0.128 DBMET02630 | ||
| 0.211 | 0.009 | 0.211 | Creatine kinase inhibitor | 0.11 0.049 DBMET02629 0.09 0.071 DBMET02631 0.141 0.028 DBMET02632 0.113 0.047 DBMET02633 0.163 0.019 DBMET02634 | ||
| 0.295 | 0.097 | 0.295 | Transcription factor NF kappa B inhibitor | 0.249 0.128 DBMET02629 0.211 0.159 DBMET02630 0.233 0.14 DBMET02633 | ||
| 0.202 | 0.005 | 0.202 | Histone deacetylase SIRT1 stimulant | 0.171 0.006 DBMET02629 0.067 0.058 DBMET02630 0.097 0.03 DBMET02632 0.064 0.063 DBMET02634 | ||
| 0.202 | 0.005 | 0.202 | Histone deacetylase stimulant | 0.171 0.006 DBMET02629 0.067 0.058 DBMET02630 0.097 0.03 DBMET02632 0.064 0.063 DBMET02634 | ||
| 0.24 | 0.044 | 0.246 | Neurotrophic factor enhancer | 0.238 0.046 DBMET02629 0.246 0.04 DBMET02630 0.164 0.118 DBMET02632 | DBMET02630 | |
| 0.212 | 0.017 | 0.212 | Carbonic anhydrase XV inhibitor | 0.107 0.059 DBMET02629 0.093 0.077 DBMET02632 | ||
| 0.204 | 0.01 | 0.302 | Glutamate receptor agonist | 0.302 0.005 DBMET02629 0.103 0.035 DBMET02630 0.068 0.065 DBMET02631 0.076 0.057 DBMET02632 0.118 0.027 DBMET02634 | DBMET02629 | |
| 0.241 | 0.047 | 0.241 | Non-steroidal antiinflammatory agent | 0.152 0.112 DBMET02630 0.141 0.128 DBMET02631 | ||
| 0.2 | 0.007 | 0.2 | DOPA decarboxylase inhibitor | 0.169 0.013 DBMET02629 0.111 0.057 DBMET02630 0.145 0.024 DBMET02631 0.111 0.057 DBMET02632 0.119 0.046 DBMET02633 0.11 0.058 DBMET02634 | ||
| 0.245 | 0.054 | 0.443 | Death-associated protein kinase 3 inhibitor | 0.443 0.011 DBMET02629 | DBMET02629 | |
| 0.194 | 0.005 | 0.194 | DNA gyrase inhibitor | 0.076 0.03 DBMET02629 0.073 0.032 DBMET02630 0.061 0.047 DBMET02631 0.102 0.017 DBMET02632 0.127 0.011 DBMET02634 | ||
| 0.256 | 0.069 | 0.364 | Dyrk kinase inhibitor | 0.364 0.034 DBMET02629 | DBMET02629 | |
| 0.205 | 0.02 | 0.205 | Aminopeptidase B inhibitor | 0.15 0.038 DBMET02629 0.199 0.021 DBMET02630 0.169 0.03 DBMET02631 0.104 0.063 DBMET02632 0.126 0.049 DBMET02634 | ||
| 0.198 | 0.014 | 0.198 | Protein kinase C gamma inhibitor | 0.194 0.015 DBMET02629 0.108 0.064 DBMET02631 0.139 0.038 DBMET02632 0.139 0.039 DBMET02633 0.162 0.025 DBMET02634 | ||
| 0.212 | 0.028 | 0.227 | Hemostatic | 0.212 0.028 DBMET02629 0.227 0.025 DBMET02630 0.153 0.064 DBMET02631 0.166 0.052 DBMET02634 | DBMET02630 | |
| 0.202 | 0.019 | 0.202 | Xanthine oxidase inhibitor | 0.086 0.078 DBMET02632 | ||
| 0.187 | 0.005 | 0.187 | Ca2+-transporting ATPase inhibitor | 0.144 0.059 DBMET02629 0.133 0.104 DBMET02630 0.136 0.092 DBMET02631 0.174 0.01 DBMET02632 0.141 0.069 DBMET02633 0.146 0.054 DBMET02634 | ||
| 0.221 | 0.043 | 0.246 | Histone acetyltransferase inhibitor | 0.213 0.051 DBMET02629 0.149 0.142 DBMET02630 0.199 0.071 DBMET02631 0.162 0.123 DBMET02632 0.246 0.027 DBMET02634 | DBMET02634 | |
| 0.208 | 0.03 | 0.208 | Alkaline phosphatase inhibitor | 0.169 0.048 DBMET02629 0.168 0.049 DBMET02630 | ||
| 0.191 | 0.014 | 0.191 | HIV-1 integrase (Overall Integration) inhibitor | 0.119 0.04 DBMET02629 0.143 0.028 DBMET02630 0.138 0.03 DBMET02632 0.086 0.07 DBMET02633 | ||
| 0.179 | 0.004 | 0.188 | Thromboxane synthase inhibitor | 0.084 0.01 DBMET02629 0.188 0.004 DBMET02630 0.057 0.032 DBMET02631 0.064 0.022 DBMET02632 | DBMET02630 | |
| 0.204 | 0.029 | 0.204 | Arachidonic acid antagonist | 0.139 0.101 DBMET02629 0.151 0.087 DBMET02630 0.161 0.076 DBMET02632 | ||
| 0.207 | 0.033 | 0.207 | Insulin secretagoues | 0.155 0.069 DBMET02630 | ||
| 0.252 | 0.078 | 0.47 | Aryl hydrocarbon receptor agonist | 0.47 0.027 DBMET02629 0.24 0.083 DBMET02631 0.174 0.118 DBMET02632 0.175 0.117 DBMET02633 0.372 0.043 DBMET02634 | DBMET02629 | |
| 0.181 | 0.011 | 0.181 | Heat shock protein 70 antagonist | 0.16 0.028 DBMET02629 0.134 0.1 DBMET02630 0.13 0.122 DBMET02631 0.172 0.016 DBMET02632 0.151 0.043 DBMET02633 0.148 0.049 DBMET02634 | ||
| 0.178 | 0.009 | 0.178 | Argininosuccinate synthase inhibitor | 0.071 0.03 DBMET02629 0.065 0.033 DBMET02630 0.058 0.039 DBMET02631 0.059 0.037 DBMET02632 | ||
| 0.174 | 0.007 | 0.177 | Acetylcholine release stimulant | 0.177 0.007 DBMET02629 0.129 0.036 DBMET02630 0.146 0.019 DBMET02632 0.106 0.074 DBMET02634 | DBMET02629 | |
| 0.186 | 0.019 | 0.186 | Carbonic anhydrase III inhibitor | 0.086 0.081 DBMET02629 0.085 0.083 DBMET02630 0.139 0.033 DBMET02631 | ||
| 0.181 | 0.019 | 0.181 | Catalase inhibitor | 0.068 0.057 DBMET02629 0.138 0.029 DBMET02630 0.142 0.028 DBMET02632 0.116 0.034 DBMET02634 | ||
| 0.171 | 0.011 | 0.171 | Macrophage migration inhibitory factor inhibitor | 0.07 0.066 DBMET02632 | ||
| 0.205 | 0.046 | 0.415 | Heat shock protein 90 alpha antagonist | 0.362 0.008 DBMET02629 0.415 0.005 DBMET02631 0.134 0.106 DBMET02632 0.236 0.032 DBMET02633 0.283 0.018 DBMET02634 | DBMET02631 | |
| 0.165 | 0.008 | 0.165 | Ornithine decarboxylase inhibitor | 0.078 0.07 DBMET02629 0.095 0.05 DBMET02630 0.091 0.055 DBMET02632 | ||
| 0.189 | 0.033 | 0.189 | Neurotrophic factor | 0.18 0.038 DBMET02631 | ||
| 0.158 | 0.004 | 0.158 | TRPM8 blocker | 0.051 0.015 DBMET02629 0.043 0.021 DBMET02632 | ||
| 0.178 | 0.026 | 0.178 | Sphingosine 1-phosphate receptor 5 antagonist | 0.158 0.049 DBMET02629 0.144 0.072 DBMET02633 0.134 0.091 DBMET02634 | ||
| 0.162 | 0.011 | 0.162 | Aminopeptidase I inhibitor | 0.132 0.016 DBMET02629 0.159 0.011 DBMET02630 0.098 0.029 DBMET02631 0.087 0.036 DBMET02632 0.068 0.056 DBMET02633 0.079 0.043 DBMET02634 | ||
| 0.159 | 0.008 | 0.159 | Prostaglandin E2 antagonist | 0.072 0.023 DBMET02632 | ||
| 0.159 | 0.008 | 0.159 | Acyl-CoA dehydrogenase inhibitor | 0.07 0.026 DBMET02629 0.068 0.028 DBMET02630 0.071 0.026 DBMET02632 0.09 0.019 DBMET02634 | ||
| 0.178 | 0.029 | 0.178 | Antibacterial (Helicobacter pylori) | 0.138 0.058 DBMET02629 0.131 0.065 DBMET02630 0.175 0.031 DBMET02632 0.116 0.088 DBMET02634 | ||
| 0.16 | 0.012 | 0.16 | CC chemokine 6 receptor antagonist | 0.142 0.035 DBMET02629 | ||
| 0.275 | 0.131 | 0.275 | Immunosuppressant | |||
| 0.216 | 0.073 | 0.216 | Pyruvate kinase inhibitor | 0.214 0.074 DBMET02629 0.196 0.083 DBMET02631 0.155 0.111 DBMET02632 0.152 0.114 DBMET02634 | ||
| 0.238 | 0.095 | 0.333 | Transcription factor STAT inhibitor | 0.333 0.04 DBMET02629 0.231 0.101 DBMET02631 0.306 0.053 DBMET02633 0.21 0.124 DBMET02634 | DBMET02629 | |
| 0.199 | 0.057 | 0.343 | Lipocortins synthesis antagonist | 0.16 0.092 DBMET02632 0.343 0.014 DBMET02633 | DBMET02633 | |
| 0.192 | 0.05 | 0.192 | Phospholipase C inhibitor | 0.183 0.058 DBMET02629 0.175 0.066 DBMET02630 0.175 0.067 DBMET02631 0.143 0.122 DBMET02633 0.174 0.068 DBMET02634 | ||
| 0.224 | 0.085 | 0.296 | Platelet antagonist | 0.296 0.054 DBMET02630 | DBMET02630 | |
| 0.161 | 0.022 | 0.161 | AMP-activated protein kinase stimulant | 0.109 0.06 DBMET02629 0.102 0.068 DBMET02630 0.096 0.076 DBMET02634 | ||
| 0.158 | 0.02 | 0.158 | Carbonic anhydrase XIII inhibitor | 0.072 0.056 DBMET02631 | ||
| 0.211 | 0.074 | 0.411 | Platelet aggregation inhibitor | 0.151 0.127 DBMET02629 0.273 0.043 DBMET02630 0.411 0.017 DBMET02631 0.158 0.119 DBMET02632 | DBMET02631 | |
| 0.234 | 0.097 | 0.334 | 5 Hydroxytryptamine release stimulant | 0.258 0.085 DBMET02629 0.334 0.06 DBMET02632 0.27 0.08 DBMET02633 0.247 0.09 DBMET02634 | DBMET02632 | |
| 0.161 | 0.024 | 0.161 | TRPA1 agonist | 0.152 0.029 DBMET02629 0.108 0.074 DBMET02630 | ||
| 0.186 | 0.05 | 0.186 | Phospholipase A2 inhibitor | 0.121 0.115 DBMET02629 0.129 0.102 DBMET02630 0.129 0.102 DBMET02631 0.127 0.105 DBMET02632 | ||
| 0.144 | 0.009 | 0.144 | Mannitol-1-phosphate 5-dehydrogenase inhibitor | 0.105 0.013 DBMET02629 0.086 0.018 DBMET02630 0.06 0.034 DBMET02631 0.076 0.022 DBMET02632 0.05 0.048 DBMET02634 | ||
| 0.17 | 0.035 | 0.17 | Adenylate cyclase stimulant | 0.144 0.073 DBMET02629 0.152 0.059 DBMET02630 0.139 0.084 DBMET02632 | ||
| 0.169 | 0.035 | 0.169 | Interleukin 4 antagonist | 0.13 0.071 DBMET02629 0.116 0.091 DBMET02630 | ||
| 0.14 | 0.007 | 0.14 | AMPA receptor antagonist | 0.046 0.035 DBMET02630 0.095 0.013 DBMET02631 | ||
| 0.147 | 0.015 | 0.147 | Histamine N-methyltransferase inhibitor | 0.128 0.025 DBMET02629 0.112 0.036 DBMET02632 0.119 0.03 DBMET02634 | ||
| 0.138 | 0.008 | 0.138 | Purinergic P2X1 antagonist | |||
| 0.165 | 0.036 | 0.165 | Cathepsin H inhibitor | 0.14 0.054 DBMET02629 0.103 0.101 DBMET02630 0.107 0.094 DBMET02631 0.11 0.089 DBMET02634 | ||
| 0.181 | 0.053 | 0.181 | Diuretic | 0.155 0.073 DBMET02630 0.152 0.076 DBMET02632 | ||
| 0.132 | 0.006 | 0.132 | Plasminogen activator inhibitor antagonist | 0.088 0.013 DBMET02632 | ||
| 0.13 | 0.004 | 0.13 | Glutamate (mGluR7) antagonist | 0.109 0.007 DBMET02629 0.071 0.041 DBMET02630 0.076 0.033 DBMET02631 0.123 0.004 DBMET02632 0.091 0.017 DBMET02633 0.103 0.009 DBMET02634 | ||
| 0.166 | 0.041 | 0.166 | Monophenol monooxygenase inhibitor | 0.105 0.072 DBMET02631 | ||
| 0.134 | 0.009 | 0.134 | Granulocyte macrophage colony stimulating factor agonist | 0.124 0.014 DBMET02629 0.114 0.02 DBMET02630 0.089 0.053 DBMET02631 0.1 0.034 DBMET02632 | ||
| 0.14 | 0.015 | 0.146 | Lanosterol 14 alpha demethylase inhibitor | 0.146 0.013 DBMET02629 0.134 0.019 DBMET02630 0.087 0.078 DBMET02631 0.086 0.079 DBMET02632 | DBMET02629 | |
| 0.131 | 0.006 | 0.131 | Glutamate (mGluR group III) agonist | 0.076 0.014 DBMET02629 0.042 0.031 DBMET02630 | ||
| 0.129 | 0.004 | 0.129 | DNA gyrase subunit B inhibitor | 0.071 0.006 DBMET02629 0.087 0.005 DBMET02630 0.052 0.012 DBMET02634 | ||
| 0.168 | 0.045 | 0.198 | MAP kinase 3 inhibitor | 0.198 0.024 DBMET02629 0.135 0.094 DBMET02630 0.129 0.11 DBMET02632 0.133 0.099 DBMET02633 0.165 0.048 DBMET02634 | DBMET02629 | |
| 0.191 | 0.072 | 0.315 | Growth factor agonist | 0.315 0.012 DBMET02629 0.265 0.025 DBMET02630 0.175 0.094 DBMET02631 | DBMET02629 | |
| 0.148 | 0.029 | 0.148 | Mediator release inhibitor | 0.094 0.077 DBMET02630 | ||
| 0.166 | 0.048 | 0.166 | Interleukin 1 antagonist | 0.123 0.084 DBMET02629 | ||
| 0.121 | 0.004 | 0.121 | Retinoid X alpha receptor agonist | |||
| 0.15 | 0.033 | 0.169 | Mucolytic | 0.169 0.023 DBMET02630 0.109 0.065 DBMET02632 | DBMET02630 | |
| 0.164 | 0.047 | 0.164 | NADPH oxidase inhibitor | 0.125 0.076 DBMET02629 0.114 0.091 DBMET02630 0.126 0.076 DBMET02634 | ||
| 0.175 | 0.059 | 0.263 | Protein-tyrosine phosphatase inhibitor | 0.263 0.028 DBMET02631 | DBMET02631 | |
| 0.181 | 0.067 | 0.394 | Tumour necrosis factor antagonist | 0.288 0.02 DBMET02629 0.394 0.007 DBMET02631 0.179 0.068 DBMET02633 0.159 0.089 DBMET02634 | DBMET02631 | |
| 0.119 | 0.004 | 0.119 | Urate transporter 1 inhibitor | |||
| 0.168 | 0.054 | 0.178 | Glycogen synthase kinase-3 alpha inhibitor | 0.178 0.049 DBMET02629 0.109 0.094 DBMET02631 0.114 0.09 DBMET02634 | DBMET02629 | |
| 0.124 | 0.011 | 0.124 | Glycine receptor agonist | 0.103 0.019 DBMET02629 0.07 0.054 DBMET02630 0.072 0.051 DBMET02631 0.069 0.057 DBMET02632 0.095 0.024 DBMET02634 | ||
| 0.151 | 0.038 | 0.207 | Death-associated protein kinase 1 inhibitor | 0.207 0.006 DBMET02629 0.149 0.041 DBMET02630 | DBMET02629 | |
| 0.172 | 0.059 | 0.172 | Neurotensin receptor agonist | 0.17 0.062 DBMET02629 0.169 0.064 DBMET02630 0.138 0.135 DBMET02631 0.155 0.089 DBMET02632 0.141 0.125 DBMET02633 | ||
| 0.115 | 0.002 | 0.115 | Nerve growth factor antagonist | 0.072 0.005 DBMET02629 0.042 0.031 DBMET02630 0.04 0.035 DBMET02631 0.076 0.004 DBMET02632 0.045 0.025 DBMET02634 | ||
| 0.176 | 0.064 | 0.248 | Thrombolytic | 0.248 0.034 DBMET02630 0.136 0.093 DBMET02632 | DBMET02630 | |
| 0.129 | 0.017 | 0.272 | Glutamate (mGluR) agonist | 0.272 0.005 DBMET02629 0.074 0.034 DBMET02634 | DBMET02629 | |
| 0.194 | 0.083 | 0.206 | DNA methylase inhibitor | 0.143 0.124 DBMET02630 0.174 0.097 DBMET02633 0.206 0.075 DBMET02634 | DBMET02634 | |
| 0.147 | 0.036 | 0.147 | Interleukin 8 antagonist | 0.132 0.048 DBMET02629 0.121 0.06 DBMET02630 0.113 0.072 DBMET02631 0.101 0.093 DBMET02632 | ||
| 0.114 | 0.003 | 0.114 | Retinoid X gamma receptor agonist | 0.024 0.014 DBMET02632 | ||
| 0.186 | 0.076 | 0.186 | DNA methyltransferase I inhibitor | 0.135 0.123 DBMET02630 0.144 0.111 DBMET02632 0.138 0.119 DBMET02634 | ||
| 0.182 | 0.072 | 0.182 | Dual specificity phosphatase 3 inhibitor | |||
| 0.206 | 0.097 | 0.206 | Glucose-6-phosphate dehydrogenase-6-phosphogluconolactonase inhibitor | 0.148 0.145 DBMET02629 | ||
| 0.192 | 0.083 | 0.377 | Dual specificity tyrosine-phosphorylation regulated kinase 3 inhibitor | 0.377 0.013 DBMET02629 0.161 0.109 DBMET02634 | DBMET02629 | |
| 0.213 | 0.105 | 0.384 | DNA damaging | 0.231 0.092 DBMET02629 0.215 0.104 DBMET02630 0.33 0.047 DBMET02631 0.339 0.044 DBMET02632 0.384 0.032 DBMET02633 0.249 0.081 DBMET02634 | DBMET02633 | |
| 0.122 | 0.015 | 0.122 | GABA aminotransferase inhibitor | |||
| 0.142 | 0.036 | 0.142 | Photosensitizer | 0.101 0.086 DBMET02630 0.1 0.089 DBMET02632 | ||
| 0.12 | 0.014 | 0.12 | Prostaglandin EP2 antagonist | 0.069 0.033 DBMET02630 | ||
| 0.117 | 0.012 | 0.117 | Glutamate (mGluR1) antagonist | 0.068 0.032 DBMET02629 0.068 0.032 DBMET02630 0.086 0.02 DBMET02631 | ||
| 0.133 | 0.029 | 0.152 | Protein kinase C delta inhibitor | 0.152 0.02 DBMET02629 | DBMET02629 | |
| 0.108 | 0.004 | 0.108 | Glutamate (mGluR3) antagonist | 0.041 0.02 DBMET02629 0.038 0.023 DBMET02632 | ||
| 0.146 | 0.043 | 0.146 | Interleukin 1b antagonist | 0.115 0.067 DBMET02629 | ||
| 0.194 | 0.092 | 0.289 | EphB2 antagonist | 0.289 0.039 DBMET02629 | DBMET02629 | |
| 0.136 | 0.033 | 0.175 | Gastric antisecretory | 0.139 0.032 DBMET02629 0.121 0.042 DBMET02630 0.175 0.018 DBMET02631 0.103 0.062 DBMET02632 | DBMET02631 | |
| 0.125 | 0.023 | 0.125 | Adrenaline agonist | 0.077 0.061 DBMET02629 0.097 0.039 DBMET02630 | ||
| 0.143 | 0.04 | 0.161 | Falcipain 3 inhibitor | 0.151 0.036 DBMET02629 0.143 0.04 DBMET02630 0.135 0.044 DBMET02632 0.161 0.032 DBMET02634 | DBMET02634 | |
| 0.116 | 0.014 | 0.116 | Prostaglandin antagonist | |||
| 0.109 | 0.008 | 0.109 | Glutamate (mGluR6) antagonist | 0.077 0.027 DBMET02629 0.073 0.033 DBMET02631 0.066 0.05 DBMET02632 | ||
| 0.173 | 0.072 | 0.173 | Mcl-1 antagonist | |||
| 0.103 | 0.004 | 0.103 | Retinoid X receptor agonist | |||
| 0.103 | 0.004 | 0.103 | Retinoic acid receptor agonist | |||
| 0.105 | 0.007 | 0.105 | Kainate receptor antagonist | 0.041 0.028 DBMET02631 0.045 0.025 DBMET02632 | ||
| 0.143 | 0.045 | 0.149 | Beta amyloid protein antagonist | 0.149 0.042 DBMET02629 0.138 0.049 DBMET02630 0.129 0.058 DBMET02632 0.116 0.071 DBMET02634 | DBMET02629 | |
| 0.121 | 0.024 | 0.121 | Phosphodiesterase 6D inhibitor | 0.092 0.069 DBMET02629 0.098 0.055 DBMET02632 | ||
| 0.102 | 0.004 | 0.505 | Protocollagen prolyl hydroxylase inhibitor | 0.03 0.015 DBMET02629 0.505 0.002 DBMET02630 | DBMET02630 | |
| 0.147 | 0.051 | 0.147 | Cyclooxygenase 3 inhibitor | 0.108 0.091 DBMET02632 | ||
| 0.106 | 0.009 | 0.106 | Thromboxane antagonist | 0.064 0.029 DBMET02630 | ||
| 0.11 | 0.014 | 0.11 | Neuraminidase (influenza) inhibitor | |||
| 0.099 | 0.004 | 0.099 | Pregnane X receptor antagonist | 0.055 0.044 DBMET02629 0.062 0.026 DBMET02631 0.065 0.022 DBMET02632 | ||
| 0.213 | 0.118 | 0.213 | Transcription factor STAT3 inhibitor | 0.203 0.13 DBMET02629 0.175 0.172 DBMET02631 0.186 0.155 DBMET02633 | ||
| 0.113 | 0.017 | 0.12 | D-Ala-D-Ala ligase inhibitor | 0.095 0.036 DBMET02629 0.079 0.073 DBMET02630 0.088 0.049 DBMET02631 0.12 0.014 DBMET02632 0.116 0.015 DBMET02633 0.091 0.043 DBMET02634 | DBMET02632 | |
| 0.12 | 0.026 | 0.125 | Glutamate (mGluR) antagonist | 0.125 0.024 DBMET02629 | DBMET02629 | |
| 0.138 | 0.045 | 0.138 | Sphingosine 1-phosphate receptor 4 antagonist | 0.117 0.079 DBMET02629 0.115 0.082 DBMET02631 | ||
| 0.096 | 0.003 | 0.096 | 3-Hydroxyanthranilate 3,4-dioxygenase inhibitor | 0.046 0.021 DBMET02629 0.072 0.004 DBMET02631 0.05 0.015 DBMET02632 | ||
| 0.168 | 0.076 | 0.168 | Dual specificity phosphatase inhibitor | |||
| 0.184 | 0.093 | 0.501 | MAP kinase kinase 2 inhibitor | 0.378 0.015 DBMET02629 0.151 0.12 DBMET02630 0.202 0.08 DBMET02631 0.17 0.104 DBMET02632 0.299 0.035 DBMET02633 0.501 0.005 DBMET02634 | DBMET02634 | |
| 0.113 | 0.022 | 0.129 | Nicotinic alpha4beta2 receptor antagonist | 0.128 0.014 DBMET02629 0.129 0.014 DBMET02632 0.086 0.044 DBMET02634 | DBMET02632 | |
| 0.117 | 0.026 | 0.117 | Dual specificity tyrosine-phosphorylation regulated kinase 2 inhibitor | 0.08 0.064 DBMET02629 0.087 0.052 DBMET02634 | ||
| 0.133 | 0.043 | 0.155 | Caspase 3 inhibitor | 0.155 0.024 DBMET02630 | DBMET02630 | |
| 0.16 | 0.07 | 0.292 | Cyclin-dependent kinase 8 inhibitor | 0.292 0.009 DBMET02629 0.135 0.096 DBMET02630 0.187 0.045 DBMET02631 0.134 0.097 DBMET02633 0.189 0.044 DBMET02634 | DBMET02629 | |
| 0.095 | 0.005 | 0.095 | Kainate receptor 2 antagonist | 0.046 0.018 DBMET02631 0.043 0.02 DBMET02632 | ||
| 0.118 | 0.03 | 0.118 | NAD(P)H dehydrogenase (quinone) inhibitor | 0.096 0.04 DBMET02632 0.075 0.056 DBMET02634 | ||
| 0.092 | 0.004 | 0.092 | Retinoic acid alpha receptor agonist | |||
| 0.104 | 0.016 | 0.104 | 3-Oxoacyl-[acyl-carrier-protein] synthase inhibitor | 0.054 0.048 DBMET02629 | ||
| 0.115 | 0.028 | 0.149 | Acetylcholine nicotinic agonist | 0.149 0.017 DBMET02629 0.094 0.042 DBMET02631 0.072 0.068 DBMET02632 0.093 0.043 DBMET02634 | DBMET02629 | |
| 0.192 | 0.105 | 0.192 | Antiamyloidogenic | 0.17 0.123 DBMET02630 | ||
| 0.121 | 0.034 | 0.217 | MAP kinase kinase 1 inhibitor | 0.177 0.008 DBMET02629 0.115 0.039 DBMET02631 0.115 0.039 DBMET02632 0.171 0.01 DBMET02633 0.217 0.004 DBMET02634 | DBMET02634 | |
| 0.102 | 0.016 | 0.102 | Ornithine carbamoyltransferase inhibitor | 0.052 0.038 DBMET02629 0.076 0.023 DBMET02630 | ||
| 0.101 | 0.016 | 0.101 | GABA B receptor agonist | 0.076 0.051 DBMET02629 0.08 0.043 DBMET02630 | ||
| 0.103 | 0.018 | 0.103 | NMDA receptor agonist | 0.075 0.032 DBMET02630 | ||
| 0.14 | 0.055 | 0.14 | Sphingosine 1-phosphate receptor 2 antagonist | 0.135 0.064 DBMET02629 0.135 0.064 DBMET02633 0.127 0.08 DBMET02634 | ||
| 0.129 | 0.045 | 0.202 | Transcription factor STAT6 inhibitor | 0.202 0.007 DBMET02629 0.103 0.098 DBMET02630 0.127 0.049 DBMET02631 0.115 0.07 DBMET02632 0.147 0.025 DBMET02633 0.132 0.041 DBMET02634 | DBMET02629 | |
| 0.095 | 0.01 | 0.109 | Potassium channel intermediate-conductance Ca-activated blocker | 0.109 0.007 DBMET02629 0.059 0.044 DBMET02632 | DBMET02629 | |
| 0.103 | 0.02 | 0.103 | Carbamoyl phosphate synthetase inhibitor | 0.086 0.026 DBMET02629 0.075 0.031 DBMET02630 0.061 0.042 DBMET02631 0.065 0.038 DBMET02632 0.099 0.021 DBMET02634 | ||
| 0.087 | 0.004 | 0.087 | Retinoid X beta receptor agonist | |||
| 0.097 | 0.015 | 0.097 | Protein kinase C beta inhibitor | 0.095 0.016 DBMET02629 0.076 0.037 DBMET02632 0.079 0.031 DBMET02634 | ||
| 0.088 | 0.006 | 0.088 | Fumarate hydratase inhibitor | 0.033 0.025 DBMET02629 0.031 0.027 DBMET02630 0.033 0.026 DBMET02632 0.038 0.021 DBMET02634 | ||
| 0.094 | 0.013 | 0.094 | Dihydroorotate dehydrogenase inhibitor | |||
| 0.098 | 0.016 | 0.098 | Neuraminidase inhibitor | |||
| 0.091 | 0.01 | 0.111 | Oleamide hydrolase inhibitor | 0.111 0.008 DBMET02629 0.044 0.033 DBMET02630 0.042 0.035 DBMET02631 0.039 0.038 DBMET02632 | DBMET02629 | |
| 0.097 | 0.016 | 0.134 | S-adenosyl-L-methionine decarboxylase inhibitor | 0.134 0.004 DBMET02629 0.078 0.041 DBMET02630 0.102 0.012 DBMET02631 0.072 0.054 DBMET02632 0.085 0.028 DBMET02633 0.095 0.017 DBMET02634 | DBMET02629 | |
| 0.12 | 0.039 | 0.12 | Anabolic | 0.087 0.084 DBMET02630 0.095 0.069 DBMET02632 | ||
| 0.091 | 0.01 | 0.091 | Thromboxane A2 antagonist | 0.06 0.028 DBMET02630 | ||
| 0.084 | 0.004 | 0.084 | Geranyltranstransferase inhibitor | 0.064 0.011 DBMET02629 0.068 0.008 DBMET02630 0.069 0.008 DBMET02632 0.042 0.033 DBMET02633 | ||
| 0.093 | 0.014 | 0.093 | Prostaglandin F2 alpha antagonist | 0.093 0.014 DBMET02632 | ||
| 0.102 | 0.023 | 0.169 | Amidase inhibitor | 0.169 0.008 DBMET02629 0.1 0.024 DBMET02630 0.104 0.022 DBMET02631 0.078 0.039 DBMET02632 0.106 0.021 DBMET02634 | DBMET02629 | |
| 0.083 | 0.004 | 0.083 | Methionyl aminopeptidase 2 inhibitor | 0.023 0.02 DBMET02629 | ||
| 0.092 | 0.013 | 0.13 | Exportin-1 inhibitor | 0.13 0.004 DBMET02629 0.067 0.05 DBMET02630 0.078 0.029 DBMET02631 0.066 0.052 DBMET02632 0.099 0.009 DBMET02634 | DBMET02629 | |
| 0.083 | 0.004 | 0.083 | Purinergic P2Y14 antagonist | 0.034 0.017 DBMET02631 | ||
| 0.086 | 0.008 | 0.086 | Guanylate cyclase stimulant | |||
| 0.085 | 0.007 | 0.085 | Adenine nucleotide translocase inhibitor | |||
| 0.189 | 0.113 | 0.302 | Peptidyltransferase inhibitor | 0.261 0.044 DBMET02629 0.302 0.024 DBMET02630 0.217 0.079 DBMET02631 0.225 0.071 DBMET02633 0.232 0.065 DBMET02634 | DBMET02630 | |
| 0.109 | 0.033 | 0.109 | Bile acid receptor antagonist | 0.088 0.079 DBMET02630 0.086 0.083 DBMET02632 | ||
| 0.084 | 0.009 | 0.084 | Dihydroorotate oxidase inhibitor | |||
| 0.143 | 0.068 | 0.143 | Amylase inhibitor | |||
| 0.109 | 0.034 | 0.109 | Carbonic anhydrase VI inhibitor | 0.089 0.048 DBMET02631 | ||
| 0.077 | 0.003 | 0.077 | Nicotinic acid receptor 2 antagonist | 0.026 0.02 DBMET02632 | ||
| 0.082 | 0.009 | 0.082 | Lysophosphatidic acid 3 receptor antagonist | 0.049 0.037 DBMET02630 | ||
| 0.145 | 0.072 | 0.183 | MAP kinase kinase 4 inhibitor | 0.183 0.022 DBMET02629 | DBMET02629 | |
| 0.122 | 0.049 | 0.128 | Expectorant | 0.128 0.045 DBMET02630 | DBMET02630 | |
| 0.087 | 0.013 | 0.087 | MDM2 inhibitor | 0.064 0.057 DBMET02632 | ||
| 0.077 | 0.004 | 0.077 | Kynurenine 3 monooxygenase inhibitor | |||
| 0.081 | 0.008 | 0.096 | Ryanodine receptor antagonist | 0.096 0.005 DBMET02632 0.056 0.053 DBMET02633 | DBMET02632 | |
| 0.092 | 0.02 | 0.152 | Phospholipase D inhibitor | 0.102 0.014 DBMET02629 0.152 0.003 DBMET02630 0.065 0.064 DBMET02632 0.083 0.03 DBMET02634 | DBMET02630 | |
| 0.077 | 0.004 | 0.077 | NMDA 2D receptor antagonist | |||
| 0.08 | 0.009 | 0.08 | Dihydroorotase inhibitor | |||
| 0.077 | 0.005 | 0.077 | Dopamine beta hydroxylase inhibitor | 0.071 0.008 DBMET02629 0.046 0.039 DBMET02630 0.063 0.013 DBMET02632 0.05 0.029 DBMET02633 0.047 0.038 DBMET02634 | ||
| 0.083 | 0.012 | 0.193 | Glutamate (mGluR group I) agonist | 0.193 0.004 DBMET02629 0.065 0.019 DBMET02630 0.045 0.037 DBMET02631 0.094 0.009 DBMET02634 | DBMET02629 | |
| 0.145 | 0.074 | 0.157 | Thiol protease inhibitor | 0.15 0.068 DBMET02629 0.157 0.063 DBMET02630 | DBMET02630 | |
| 0.076 | 0.006 | 0.076 | Glutamate (mGluR4) agonist | 0.049 0.011 DBMET02629 | ||
| 0.072 | 0.003 | 0.072 | Retinoic acid beta receptor antagonist | |||
| 0.105 | 0.036 | 0.18 | Acetylcholine nicotinic antagonist | 0.113 0.033 DBMET02629 0.18 0.015 DBMET02632 0.083 0.051 DBMET02633 0.073 0.063 DBMET02634 | DBMET02632 | |
| 0.081 | 0.013 | 0.081 | Topoisomerase II beta inhibitor | 0.05 0.033 DBMET02630 | ||
| 0.073 | 0.005 | 0.073 | Glutamate (mGluR8) agonist | 0.043 0.018 DBMET02629 0.039 0.023 DBMET02631 0.037 0.027 DBMET02632 | ||
| 0.094 | 0.027 | 0.116 | Neuronal nicotinic receptor antagonist | 0.105 0.022 DBMET02629 0.116 0.019 DBMET02632 0.069 0.046 DBMET02634 | DBMET02632 | |
| 0.104 | 0.037 | 0.104 | Glutamate release inhibitor | 0.103 0.038 DBMET02632 | ||
| 0.23 | 0.164 | 0.308 | Calpain 2 inhibitor | 0.308 0.109 DBMET02631 | DBMET02631 | |
| 0.07 | 0.004 | 0.07 | Protein kinase (CK2) beta inhibitor | 0.052 0.007 DBMET02629 0.031 0.03 DBMET02634 | ||
| 0.072 | 0.007 | 0.072 | Farnesoid X receptor agonist | |||
| 0.115 | 0.051 | 0.115 | Beta glucuronidase inhibitor | |||
| 0.081 | 0.016 | 0.081 | Sphingosine 1-phosphate receptor 3 antagonist | 0.07 0.025 DBMET02629 0.076 0.02 DBMET02630 | ||
| 0.069 | 0.005 | 0.069 | Guanylate cyclase inhibitor | 0.041 0.031 DBMET02632 | ||
| 0.125 | 0.062 | 0.195 | Cell adhesion inhibitor | 0.195 0.026 DBMET02630 | DBMET02630 | |
| 0.088 | 0.024 | 0.088 | Peroxisome proliferator-activated receptor gamma antagonist | 0.07 0.053 DBMET02630 0.076 0.041 DBMET02632 | ||
| 0.067 | 0.004 | 0.067 | Retinoic acid receptor antagonist | |||
| 0.104 | 0.041 | 0.174 | Polo-like kinase-1 inhibitor | 0.174 0.01 DBMET02629 0.089 0.064 DBMET02630 0.148 0.017 DBMET02631 0.102 0.043 DBMET02632 0.167 0.012 DBMET02633 0.159 0.014 DBMET02634 | DBMET02629 | |
| 0.144 | 0.082 | 0.378 | Dual specificity tyrosine-phosphorylation-regulated kinase 4 inhibitor | 0.378 0.01 DBMET02629 0.121 0.101 DBMET02631 | DBMET02629 | |
| 0.165 | 0.104 | 0.258 | Psychostimulant | 0.191 0.085 DBMET02629 0.144 0.121 DBMET02630 0.258 0.056 DBMET02632 0.228 0.067 DBMET02633 0.22 0.07 DBMET02634 | DBMET02632 | |
| 0.177 | 0.115 | 0.215 | 5 Hydroxytryptamine 3E antagonist | 0.215 0.041 DBMET02629 0.191 0.079 DBMET02631 0.206 0.053 DBMET02632 0.193 0.076 DBMET02633 0.195 0.071 DBMET02634 | DBMET02629 | |
| 0.15 | 0.089 | 0.329 | Protein kinase (CK1) gamma 3 inhibitor | 0.329 0.013 DBMET02629 0.132 0.111 DBMET02633 | DBMET02629 | |
| 0.145 | 0.085 | 0.211 | CF transmembrane conductance regulator agonist | 0.211 0.016 DBMET02629 0.172 0.044 DBMET02631 0.19 0.028 DBMET02633 0.153 0.07 DBMET02634 | DBMET02629 | |
| 0.065 | 0.005 | 0.065 | Retinoid X receptor antagonist | 0.042 0.021 DBMET02632 | ||
| 0.063 | 0.003 | 0.063 | Prostaglandin H2 antagonist | 0.045 0.004 DBMET02630 | ||
| 0.109 | 0.048 | 0.159 | Potassium channel (Ca-activated) activator | 0.159 0.025 DBMET02631 | DBMET02631 | |
| 0.104 | 0.044 | 0.14 | Potassium channel activator | 0.088 0.064 DBMET02629 0.14 0.024 DBMET02631 | DBMET02631 | |
| 0.146 | 0.087 | 0.146 | Melanin inhibitor | |||
| 0.134 | 0.076 | 0.173 | Cytokine production inhibitor | 0.173 0.047 DBMET02629 0.136 0.074 DBMET02634 | DBMET02629 | |
| 0.087 | 0.029 | 0.102 | MAP kinase kinase 7 inhibitor | 0.102 0.011 DBMET02629 0.08 0.047 DBMET02631 0.083 0.039 DBMET02633 0.083 0.038 DBMET02634 | DBMET02629 | |
| 0.084 | 0.026 | 0.084 | NMDA receptor glycine site agonist | 0.054 0.053 DBMET02630 | ||
| 0.106 | 0.05 | 0.16 | Interleukin 1 beta converting enzyme inhibitor | 0.113 0.042 DBMET02629 0.16 0.014 DBMET02630 0.119 0.036 DBMET02632 0.108 0.048 DBMET02633 0.097 0.062 DBMET02634 | DBMET02630 | |
| 0.061 | 0.005 | 0.061 | Uridine phosphorylase inhibitor | 0.035 0.014 DBMET02629 0.026 0.021 DBMET02632 0.044 0.01 DBMET02634 | ||
| 0.108 | 0.052 | 0.153 | Folate antagonist | 0.153 0.021 DBMET02630 | DBMET02630 | |
| 0.072 | 0.016 | 0.072 | Nicotinic alpha3beta2 receptor antagonist | 0.05 0.044 DBMET02629 0.064 0.022 DBMET02632 | ||
| 0.058 | 0.003 | 0.187 | Egl nine homolog 1 inhibitor | 0.187 0.002 DBMET02630 | DBMET02630 | |
| 0.094 | 0.039 | 0.139 | Cell adhesion molecule inhibitor | 0.139 0.018 DBMET02630 | DBMET02630 | |
| 0.06 | 0.005 | 0.06 | Free fatty acid receptor 1 antagonist | |||
| 0.058 | 0.002 | 0.058 | Nicotinic acid receptor 1 antagonist | 0.016 0.015 DBMET02629 0.016 0.014 DBMET02632 | ||
| 0.069 | 0.014 | 0.069 | Adenosine deaminase inhibitor | 0.059 0.021 DBMET02629 0.049 0.031 DBMET02630 0.063 0.019 DBMET02632 0.043 0.038 DBMET02633 0.059 0.022 DBMET02634 | ||
| 0.063 | 0.009 | 0.063 | RNA-directed RNA polymerase inhibitor | 0.031 0.029 DBMET02630 | ||
| 0.203 | 0.149 | 0.203 | 12-Lipoxygenase inhibitor | |||
| 0.06 | 0.006 | 0.06 | Angiotensin AT1 receptor antagonist | 0.051 0.016 DBMET02632 | ||
| 0.121 | 0.066 | 0.121 | Topoisomerase II inhibitor | 0.102 0.085 DBMET02632 | ||
| 0.068 | 0.014 | 0.116 | Glutamate (mGluR5) agonist | 0.116 0.005 DBMET02629 0.049 0.027 DBMET02630 0.059 0.018 DBMET02634 | DBMET02629 | |
| 0.063 | 0.009 | 0.063 | GABA uptake inhibitor | |||
| 0.071 | 0.018 | 0.071 | Myc inhibitor | |||
| 0.087 | 0.033 | 0.128 | HIV-1 integrase inhibitor | 0.076 0.041 DBMET02630 0.128 0.013 DBMET02632 0.1 0.025 DBMET02633 | DBMET02632 | |
| 0.066 | 0.013 | 0.066 | Factor III inhibitor | 0.053 0.028 DBMET02630 | ||
| 0.109 | 0.056 | 0.109 | Urease inhibitor | 0.094 0.074 DBMET02629 0.086 0.082 DBMET02630 | ||
| 0.077 | 0.024 | 0.077 | Carbonic anhydrase VB inhibitor | 0.066 0.03 DBMET02631 | ||
| 0.062 | 0.009 | 0.083 | Diamine oxidase inhibitor | 0.083 0.005 DBMET02629 0.035 0.03 DBMET02634 | DBMET02629 | |
| 0.067 | 0.014 | 0.067 | Glucose-6-phosphate isomerase inhibitor | 0.045 0.039 DBMET02630 0.049 0.031 DBMET02632 | ||
| 0.059 | 0.007 | 0.059 | Kainate receptor agonist | 0.044 0.022 DBMET02629 0.039 0.035 DBMET02630 0.041 0.028 DBMET02631 0.046 0.018 DBMET02632 0.039 0.035 DBMET02634 | ||
| 0.056 | 0.004 | 0.056 | Retinoid X alpha receptor antagonist | 0.037 0.019 DBMET02632 | ||
| 0.072 | 0.02 | 0.072 | 3(or 17)beta-hydroxysteroid dehydrogenase inhibitor | |||
| 0.138 | 0.087 | 0.338 | Heat shock protein 90 antagonist | 0.3 0.01 DBMET02629 0.338 0.006 DBMET02631 0.122 0.111 DBMET02632 0.202 0.037 DBMET02633 0.223 0.029 DBMET02634 | DBMET02631 | |
| 0.096 | 0.045 | 0.162 | Bromodomain-containing protein 2 inhibitor | 0.099 0.041 DBMET02629 0.125 0.02 DBMET02632 0.162 0.006 DBMET02634 | DBMET02634 | |
| 0.054 | 0.003 | 0.054 | Retinoic acid receptor gamma antagonist | |||
| 0.06 | 0.009 | 0.06 | AMPA 1 receptor antagonist | 0.037 0.016 DBMET02630 | ||
| 0.094 | 0.043 | 0.119 | Hematopoietic | 0.119 0.023 DBMET02630 | DBMET02630 | |
| 0.223 | 0.174 | 0.885 | Toll-Like receptor 7 agonist | 0.332 0.092 DBMET02629 0.23 0.167 DBMET02630 0.885 0.004 DBMET02631 0.23 0.167 DBMET02634 | DBMET02631 | |
| 0.083 | 0.034 | 0.2 | CDC7 inhibitor | 0.2 0.005 DBMET02629 0.062 0.054 DBMET02631 0.067 0.048 DBMET02634 | DBMET02629 | |
| 0.182 | 0.133 | 0.245 | Calpain inhibitor | 0.22 0.094 DBMET02629 0.184 0.13 DBMET02630 0.245 0.069 DBMET02631 | DBMET02631 | |
| 0.053 | 0.005 | 0.053 | Angiotensin II receptor antagonist | 0.038 0.017 DBMET02632 | ||
| 0.064 | 0.017 | 0.064 | Heparanase inhibitor | 0.055 0.032 DBMET02630 | ||
| 0.12 | 0.073 | 0.317 | MAP kinase kinase inhibitor | 0.222 0.021 DBMET02629 0.115 0.079 DBMET02631 0.156 0.048 DBMET02633 0.317 0.007 DBMET02634 | DBMET02634 | |
| 0.161 | 0.114 | 0.239 | Focal adhesion kinase 2 inhibitor | 0.239 0.043 DBMET02629 0.163 0.111 DBMET02633 0.184 0.083 DBMET02634 | DBMET02629 | |
| 0.092 | 0.046 | 0.123 | Histamine H1 receptor antagonist | 0.123 0.031 DBMET02631 0.088 0.05 DBMET02632 | DBMET02631 | |
| 0.067 | 0.021 | 0.103 | Phosphorylase inhibitor | 0.103 0.013 DBMET02630 | DBMET02630 | |
| 0.073 | 0.028 | 0.076 | Cyclin-dependent kinase 6 inhibitor | 0.076 0.025 DBMET02629 0.052 0.051 DBMET02632 | DBMET02629 | |
| 0.05 | 0.004 | 0.05 | Retinoic acid beta receptor agonist | |||
| 0.058 | 0.012 | 0.058 | Glutamate (mGluR group II) antagonist | 0.055 0.013 DBMET02629 | ||
| 0.065 | 0.019 | 0.065 | Leukotriene C antagonist | |||
| 0.049 | 0.004 | 0.049 | Retinoic acid alpha receptor antagonist | |||
| 0.051 | 0.006 | 0.051 | Prostaglandin EP1 antagonist | |||
| 0.053 | 0.009 | 0.053 | HCV NS5B polymerase inhibitor | |||
| 0.062 | 0.018 | 0.062 | Purinergic P2Y antagonist | |||
| 0.069 | 0.026 | 0.086 | Botulinum neurotoxin type A inhibitor | 0.072 0.023 DBMET02629 0.086 0.014 DBMET02630 | DBMET02630 | |
| 0.081 | 0.037 | 0.081 | Glutamate (mGluR group I) antagonist | 0.074 0.043 DBMET02629 | ||
| 0.071 | 0.028 | 0.078 | Phosphodiesterase 1C inhibitor | 0.078 0.021 DBMET02629 0.059 0.052 DBMET02634 | DBMET02629 | |
| 0.056 | 0.014 | 0.061 | Glutamate (mGluR group II) agonist | 0.061 0.012 DBMET02629 | DBMET02629 | |
| 0.057 | 0.016 | 0.057 | Glutamate (mGluR1a) antagonist | 0.046 0.023 DBMET02629 | ||
| 0.048 | 0.007 | 0.056 | Methionyl aminopeptidase 1 inhibitor | 0.056 0.005 DBMET02629 0.035 0.018 DBMET02630 0.031 0.024 DBMET02631 | DBMET02629 | |
| 0.133 | 0.092 | 0.142 | Pregnane X receptor agonist | 0.135 0.086 DBMET02629 0.142 0.07 DBMET02632 0.125 0.115 DBMET02633 | DBMET02632 | |
| 0.144 | 0.104 | 0.28 | LIM domain kinase 1 inhibitor | 0.28 0.026 DBMET02629 0.151 0.096 DBMET02633 0.144 0.104 DBMET02634 | DBMET02629 | |
| 0.146 | 0.106 | 0.156 | Cyclin-dependent kinase 3 inhibitor | 0.142 0.116 DBMET02629 0.156 0.084 DBMET02630 | DBMET02630 | |
| 0.054 | 0.014 | 0.054 | Dihydropteroate synthase inhibitor | 0.044 0.022 DBMET02630 | ||
| 0.219 | 0.18 | 0.883 | Toll-Like receptor agonist | 0.331 0.092 DBMET02629 0.238 0.16 DBMET02630 0.883 0.004 DBMET02631 0.23 0.167 DBMET02634 | DBMET02631 | |
| 0.075 | 0.036 | 0.075 | Leukotriene antagonist | |||
| 0.073 | 0.034 | 0.073 | HIV-1 integrase (Strand Transfer) inhibitor | |||
| 0.043 | 0.004 | 0.043 | Retinoid X gamma receptor antagonist | |||
| 0.077 | 0.039 | 0.077 | Carbonic anhydrase VA inhibitor | 0.076 0.04 DBMET02631 | ||
| 0.118 | 0.079 | 0.118 | M17 leucyl aminopeptidase inhibitor | |||
| 0.053 | 0.014 | 0.053 | Beta adrenoreceptor agonist | 0.047 0.024 DBMET02630 | ||
| 0.048 | 0.01 | 0.048 | CF transmembrane conductance regulator antagonist | 0.039 0.03 DBMET02632 | ||
| 0.091 | 0.053 | 0.372 | Phosphodiesterase IV inhibitor | 0.155 0.021 DBMET02629 0.372 0.004 DBMET02631 0.081 0.06 DBMET02634 | DBMET02631 | |
| 0.076 | 0.039 | 0.085 | Selectin antagonist | 0.085 0.034 DBMET02630 | DBMET02630 | |
| 0.055 | 0.017 | 0.061 | AICAR transformylase inhibitor | 0.044 0.031 DBMET02629 0.061 0.014 DBMET02630 | DBMET02630 | |
| 0.063 | 0.026 | 0.091 | Nicotinic receptor alpha7 subunit antagonist | 0.084 0.016 DBMET02629 0.091 0.014 DBMET02632 0.05 0.044 DBMET02633 0.053 0.039 DBMET02634 | DBMET02632 | |
| 0.108 | 0.071 | 0.228 | Protein-tyrosine phosphatase 1B inhibitor | 0.228 0.021 DBMET02631 | DBMET02631 | |
| 0.11 | 0.074 | 0.11 | Microtubule formation inhibitor | 0.11 0.074 DBMET02632 0.1 0.091 DBMET02634 | ||
| 0.076 | 0.04 | 0.129 | Sphingosine 1-phosphate receptor 4 agonist | 0.091 0.03 DBMET02629 0.129 0.014 DBMET02630 | DBMET02630 | |
| 0.086 | 0.05 | 0.103 | Estrogen-related receptor beta agonist | 0.078 0.075 DBMET02629 0.103 0.021 DBMET02630 0.091 0.038 DBMET02632 0.082 0.059 DBMET02634 | DBMET02630 | |
| 0.045 | 0.009 | 0.061 | Tryptophan 5 hydroxylase inhibitor | 0.042 0.012 DBMET02629 0.061 0.004 DBMET02630 | DBMET02630 | |
| 0.043 | 0.007 | 0.043 | DNA topoisomerase IV inhibitor | |||
| 0.039 | 0.003 | 0.039 | Retinoid X beta receptor antagonist | 0.02 0.016 DBMET02632 | ||
| 0.085 | 0.05 | 0.104 | Caspase 7 inhibitor | 0.082 0.056 DBMET02629 0.094 0.035 DBMET02630 0.104 0.024 DBMET02632 | DBMET02632 | |
| 0.054 | 0.019 | 0.054 | Neuraminidase (Influenza A) inhibitor | |||
| 0.039 | 0.004 | 0.039 | Retinoic acid gamma receptor agonist | |||
| 0.049 | 0.014 | 0.056 | Glutamate (mGluR2) agonist | 0.056 0.012 DBMET02629 | DBMET02629 | |
| 0.066 | 0.031 | 0.066 | Maillard reaction inhibitor | |||
| 0.092 | 0.058 | 0.092 | Thioredoxin inhibitor | 0.081 0.08 DBMET02632 | ||
| 0.039 | 0.005 | 0.063 | Glutamate (mGluR1) agonist | 0.063 0.004 DBMET02629 0.026 0.015 DBMET02630 0.039 0.005 DBMET02631 0.027 0.012 DBMET02634 | DBMET02629 | |
| 0.037 | 0.003 | 0.124 | Egl nine homolog 3 inhibitor | 0.011 0.01 DBMET02629 0.124 0.002 DBMET02630 | DBMET02630 | |
| 0.086 | 0.053 | 0.109 | Glutathione S-transferase inhibitor | 0.088 0.05 DBMET02629 0.109 0.03 DBMET02630 0.083 0.056 DBMET02632 | DBMET02630 | |
| 0.087 | 0.054 | 0.087 | Myeloperoxidase inhibitor | 0.083 0.06 DBMET02629 | ||
| 0.045 | 0.013 | 0.045 | Vanilloid 3 antagonist | 0.04 0.021 DBMET02629 | ||
| 0.067 | 0.034 | 0.096 | Carbonic anhydrase stimulant | 0.069 0.032 DBMET02629 0.096 0.019 DBMET02630 | DBMET02630 | |
| 0.041 | 0.009 | 0.041 | Glutamate (mGluR3) agonist | |||
| 0.059 | 0.027 | 0.075 | Diacylglycerol O-acyltransferase inhibitor | 0.075 0.016 DBMET02630 | DBMET02630 | |
| 0.048 | 0.016 | 0.048 | AMPA 4 receptor antagonist | 0.038 0.03 DBMET02631 | ||
| 0.044 | 0.012 | 0.044 | Carnitine palmitoyltransferase 1 inhibitor | |||
| 0.044 | 0.012 | 0.044 | Carnitine palmitoyltransferase inhibitor | |||
| 0.038 | 0.006 | 0.038 | Hexokinase stimulant | 0.019 0.015 DBMET02629 0.018 0.017 DBMET02632 | ||
| 0.093 | 0.061 | 0.127 | Protein kinase C zeta inhibitor | 0.127 0.028 DBMET02629 0.11 0.04 DBMET02633 0.096 0.056 DBMET02634 | DBMET02629 | |
| 0.04 | 0.008 | 0.06 | LFA antagonist | 0.06 0.005 DBMET02630 0.026 0.022 DBMET02632 | DBMET02630 | |
| 0.067 | 0.036 | 0.067 | Aromatase inhibitor | |||
| 0.044 | 0.013 | 0.044 | Glutamate (mGluR8) antagonist | |||
| 0.046 | 0.015 | 0.046 | Somatostatin 5 antagonist | |||
| 0.06 | 0.029 | 0.06 | Autotaxin inhibitor | |||
| 0.063 | 0.032 | 0.074 | Beta 1 adrenoreceptor antagonist | 0.055 0.04 DBMET02629 0.074 0.022 DBMET02630 | DBMET02630 | |
| 0.058 | 0.027 | 0.062 | Prolyl endopeptidase inhibitor | 0.045 0.044 DBMET02629 0.062 0.022 DBMET02630 | DBMET02630 | |
| 0.056 | 0.025 | 0.069 | CD45 antagonist | 0.069 0.016 DBMET02630 | DBMET02630 | |
| 0.145 | 0.115 | 0.196 | Hepatoprotectant | 0.142 0.118 DBMET02630 0.196 0.067 DBMET02632 | DBMET02632 | |
| 0.057 | 0.027 | 0.057 | Carbonic anhydrase XIV inhibitor | |||
| 0.046 | 0.016 | 0.046 | Phosphoglycerate kinase inhibitor | |||
| 0.069 | 0.039 | 0.069 | HIV-1 integrase (3'-Processing) inhibitor | |||
| 0.036 | 0.006 | 0.036 | Glutamate (mGluR1a) agonist | 0.032 0.008 DBMET02629 0.024 0.013 DBMET02630 0.02 0.019 DBMET02631 | ||
| 0.086 | 0.056 | 0.143 | Bcr-Abl kinase inhibitor | 0.143 0.018 DBMET02629 0.078 0.067 DBMET02630 0.103 0.038 DBMET02631 0.086 0.057 DBMET02633 | DBMET02629 | |
| 0.071 | 0.042 | 0.071 | Carbonic anhydrase V inhibitor | 0.07 0.043 DBMET02631 | ||
| 0.114 | 0.085 | 0.151 | Toll-Like receptor 2 antagonist | 0.151 0.052 DBMET02630 | DBMET02630 | |
| 0.058 | 0.029 | 0.061 | Immunoglobulin Fc receptor antagonist | 0.061 0.022 DBMET02629 | DBMET02629 | |
| 0.047 | 0.018 | 0.059 | Membrane dipeptidase inhibitor | 0.036 0.033 DBMET02629 0.059 0.01 DBMET02630 | DBMET02630 | |
| 0.185 | 0.157 | 0.185 | Lipoxygenase inhibitor | |||
| 0.143 | 0.114 | 0.143 | ATPase inhibitor | |||
| 0.036 | 0.008 | 0.036 | Kainate receptor 1 antagonist | 0.018 0.017 DBMET02632 | ||
| 0.143 | 0.114 | 0.143 | Platelet adhesion inhibitor | |||
| 0.051 | 0.023 | 0.11 | Stearoyl-CoA desaturase inhibitor | 0.055 0.02 DBMET02629 0.11 0.005 DBMET02630 | DBMET02630 | |
| 0.061 | 0.034 | 0.09 | Fatty acid synthase inhibitor | 0.067 0.028 DBMET02629 0.09 0.014 DBMET02631 | DBMET02631 | |
| 0.04 | 0.013 | 0.04 | Liver X receptor beta antagonist | |||
| 0.061 | 0.033 | 0.061 | Protein kinase C eta inhibitor | |||
| 0.046 | 0.019 | 0.056 | Alpha 1d adrenoreceptor agonist | 0.049 0.017 DBMET02629 0.056 0.013 DBMET02632 | DBMET02632 | |
| 0.045 | 0.018 | 0.045 | Arginase inhibitor | 0.034 0.027 DBMET02630 | ||
| 0.04 | 0.014 | 0.04 | AMPA 3 receptor antagonist | 0.03 0.02 DBMET02630 0.026 0.023 DBMET02631 | ||
| 0.038 | 0.012 | 0.045 | Nicotinic alpha3beta4 receptor agonist | 0.045 0.007 DBMET02629 0.034 0.015 DBMET02632 | DBMET02629 | |
| 0.069 | 0.043 | 0.088 | Potassium channel (ATP-sensitive) blocker | 0.088 0.022 DBMET02629 | DBMET02629 | |
| 0.041 | 0.015 | 0.041 | 1-Alkyl-2-acetylglycerophosphocholine esterase inhibitor | |||
| 0.031 | 0.006 | 0.031 | Lysophosphatidic acid 1 receptor antagonist | 0.02 0.017 DBMET02632 | ||
| 0.038 | 0.013 | 0.038 | Epoxide hydrolase 1 inhibitor | 0.029 0.024 DBMET02629 0.03 0.023 DBMET02630 | ||
| 0.05 | 0.025 | 0.05 | Sphingosine 1-phosphate receptor agonist | 0.043 0.032 DBMET02630 | ||
| 0.254 | 0.229 | 0.294 | MAP kinase 1 inhibitor | 0.294 0.187 DBMET02629 | DBMET02629 | |
| 0.035 | 0.01 | 0.035 | Prostaglandin EP2 agonist | |||
| 0.055 | 0.03 | 0.055 | Glucose-6-phosphate translocase inhibitor | |||
| 0.037 | 0.013 | 0.042 | Glutamate (mGluR2) antagonist | 0.042 0.011 DBMET02629 | DBMET02629 | |
| 0.069 | 0.045 | 0.074 | Leukotriene synthesis inhibitor | 0.074 0.041 DBMET02632 | DBMET02632 | |
| 0.03 | 0.007 | 0.063 | ICAM 1 antagonist | 0.041 0.004 DBMET02629 0.063 0.003 DBMET02630 | DBMET02630 | |
| 0.042 | 0.02 | 0.042 | Leukotriene C4 antagonist | |||
| 0.064 | 0.042 | 0.067 | Transcription factor RelA inhibitor | 0.067 0.035 DBMET02629 0.059 0.058 DBMET02631 | DBMET02629 | |
| 0.058 | 0.035 | 0.085 | Ribonucleoside-diphosphate reductase inhibitor | 0.056 0.036 DBMET02629 0.085 0.023 DBMET02630 0.063 0.032 DBMET02631 | DBMET02630 | |
| 0.062 | 0.041 | 0.062 | Transcription factor AP-1 inhibitor | |||
| 0.07 | 0.049 | 0.07 | Peroxisome proliferator-activated receptor gamma agonist | |||
| 0.063 | 0.042 | 0.158 | Histone deacetylase SIRT3 inhibitor | 0.158 0.004 DBMET02629 0.092 0.012 DBMET02630 0.082 0.017 DBMET02631 0.07 0.027 DBMET02633 0.077 0.02 DBMET02634 | DBMET02629 | |
| 0.164 | 0.143 | 0.253 | Immunostimulant | 0.253 0.095 DBMET02630 | DBMET02630 | |
| 0.058 | 0.037 | 0.086 | Ribonucleotide reductase inhibitor | 0.056 0.039 DBMET02629 0.086 0.024 DBMET02630 0.064 0.034 DBMET02631 | DBMET02630 | |
| 0.05 | 0.029 | 0.05 | Cytokine production stimulant | 0.049 0.032 DBMET02629 | ||
| 0.03 | 0.009 | 0.034 | Kainate receptor 5 antagonist | 0.034 0.008 DBMET02631 | DBMET02631 | |
| 0.099 | 0.078 | 0.109 | GABA receptor agonist | 0.109 0.067 DBMET02629 | DBMET02629 | |
| 0.111 | 0.092 | 0.153 | DNA repair enzyme inhibitor | 0.131 0.053 DBMET02629 0.129 0.056 DBMET02631 0.124 0.064 DBMET02633 0.153 0.029 DBMET02634 | DBMET02634 | |
| 0.052 | 0.033 | 0.07 | Beta 2 adrenoreceptor antagonist | 0.045 0.044 DBMET02629 0.07 0.017 DBMET02630 | DBMET02630 | |
| 0.048 | 0.028 | 0.051 | Mannosidase inhibitor | 0.051 0.025 DBMET02630 | DBMET02630 | |
| 0.056 | 0.038 | 0.056 | Bombesin 3 receptor antagonist | |||
| 0.088 | 0.07 | 0.144 | Pim-1 kinase inhibitor | 0.144 0.03 DBMET02629 | DBMET02629 | |
| 0.023 | 0.005 | 0.023 | Angiotensin AT1B receptor antagonist | 0.012 0.011 DBMET02632 | ||
| 0.039 | 0.021 | 0.043 | Integrin alpha2 antagonist | 0.043 0.017 DBMET02630 | DBMET02630 | |
| 0.043 | 0.025 | 0.043 | Nicotinic acid receptor 1 agonist | 0.038 0.031 DBMET02634 | ||
| 0.073 | 0.055 | 0.073 | Phosphodiesterase VI inhibitor | |||
| 0.083 | 0.066 | 0.083 | Interleukin 5 antagonist | |||
| 0.023 | 0.005 | 0.026 | CC chemokine 9 receptor antagonist | 0.019 0.009 DBMET02629 0.026 0.004 DBMET02631 | DBMET02631 | |
| 0.063 | 0.046 | 0.063 | CDC25B inhibitor | |||
| 0.044 | 0.026 | 0.044 | Heme oxygenase inhibitor | |||
| 0.035 | 0.017 | 0.035 | Prostaglandin agonist | |||
| 0.12 | 0.103 | 0.12 | Farnesoid X receptor antagonist | |||
| 0.081 | 0.064 | 0.083 | 3C-Like protease (SARS coronavirus) inhibitor | 0.083 0.061 DBMET02629 | DBMET02629 | |
| 0.044 | 0.027 | 0.066 | GABA B receptor antagonist | 0.066 0.009 DBMET02632 0.042 0.032 DBMET02633 | DBMET02632 | |
| 0.028 | 0.012 | 0.028 | Vanilloid 2 agonist | |||
| 0.031 | 0.015 | 0.052 | MAP3K8 inhibitor | 0.042 0.006 DBMET02629 0.052 0.004 DBMET02631 0.027 0.026 DBMET02634 | DBMET02631 | |
| 0.133 | 0.117 | 0.147 | Antipruritic | 0.147 0.098 DBMET02632 | DBMET02632 | |
| 0.029 | 0.014 | 0.029 | Integrin alpha2beta1 antagonist | 0.026 0.02 DBMET02630 | ||
| 0.047 | 0.032 | 0.087 | Thymidylate synthase inhibitor | 0.043 0.037 DBMET02629 0.087 0.005 DBMET02630 | DBMET02630 | |
| 0.048 | 0.033 | 0.048 | Carnitine palmitoyltransferase 1B inhibitor | |||
| 0.073 | 0.057 | 0.073 | Na+ K+ transporting ATPase inhibitor | |||
| 0.089 | 0.074 | 0.096 | Sphingomyelinase inhibitor | 0.096 0.064 DBMET02629 | DBMET02629 | |
| 0.048 | 0.033 | 0.09 | Antimetabolite | 0.048 0.033 DBMET02629 0.09 0.018 DBMET02630 0.056 0.028 DBMET02631 | DBMET02630 | |
| 0.035 | 0.02 | 0.036 | Carboxypeptidase B inhibitor | 0.036 0.018 DBMET02630 | DBMET02630 | |
| 0.024 | 0.009 | 0.024 | Neuraminidase (Influenza B) inhibitor | |||
| 0.092 | 0.077 | 0.108 | Glutamate (mGluR7) agonist | 0.108 0.045 DBMET02629 0.094 0.074 DBMET02630 | DBMET02629 | |
| 0.031 | 0.016 | 0.046 | Nicotinic alpha4beta2 receptor agonist | 0.046 0.005 DBMET02629 0.038 0.009 DBMET02631 0.028 0.021 DBMET02632 0.027 0.022 DBMET02634 | DBMET02629 | |
| 0.03 | 0.015 | 0.03 | Prostaglandin EP4 antagonist | |||
| 0.03 | 0.016 | 0.074 | Lysine carboxypeptidase inhibitor | 0.074 0.005 DBMET02630 | DBMET02630 | |
| 0.049 | 0.035 | 0.049 | Squalene epoxidase inhibitor | |||
| 0.116 | 0.103 | 0.321 | Protein kinase (CK1) gamma 1 inhibitor | 0.321 0.017 DBMET02629 | DBMET02629 | |
| 0.052 | 0.039 | 0.052 | Leukotriene B4 antagonist | |||
| 0.021 | 0.008 | 0.021 | Methylmalonyl-CoA mutase inhibitor | |||
| 0.025 | 0.012 | 0.025 | Beta 1 adrenoreceptor agonist | |||
| 0.057 | 0.045 | 0.057 | Collagenase 3 inhibitor | |||
| 0.042 | 0.03 | 0.042 | DNA gyrase subunit A inhibitor | |||
| 0.047 | 0.034 | 0.052 | Aldosterone antagonist | 0.052 0.027 DBMET02629 0.043 0.041 DBMET02632 | DBMET02629 | |
| 0.1 | 0.088 | 0.162 | Alkylator | 0.107 0.081 DBMET02630 0.098 0.09 DBMET02631 0.156 0.043 DBMET02632 0.162 0.041 DBMET02633 0.106 0.082 DBMET02634 | DBMET02633 | |
| 0.078 | 0.066 | 0.091 | Inducible nitric-oxide synthase inhibitor | 0.075 0.071 DBMET02629 0.091 0.046 DBMET02631 | DBMET02631 | |
| 0.02 | 0.008 | 0.02 | Carbonic anhydrase VIII inhibitor | |||
| 0.02 | 0.008 | 0.02 | Carbonic anhydrase X inhibitor | |||
| 0.017 | 0.005 | 0.017 | Beta 3 adrenoreceptor agonist | |||
| 0.073 | 0.061 | 0.082 | Sphingosine 1-phosphate receptor antagonist | 0.082 0.041 DBMET02630 | DBMET02630 | |
| 0.174 | 0.162 | 0.29 | 5 Hydroxytryptamine 1E antagonist | 0.29 0.036 DBMET02629 0.231 0.096 DBMET02631 0.279 0.046 DBMET02632 0.286 0.04 DBMET02633 0.27 0.054 DBMET02634 | DBMET02629 | |
| 0.02 | 0.009 | 0.022 | Kainate receptor 3 antagonist | 0.022 0.008 DBMET02631 | DBMET02631 | |
| 0.016 | 0.005 | 0.016 | Thrombopoietin agonist | 0.012 0.007 DBMET02629 | ||
| 0.058 | 0.047 | 0.065 | Phosphodiesterase 1A inhibitor | 0.065 0.03 DBMET02629 0.055 0.054 DBMET02632 0.059 0.043 DBMET02634 | DBMET02629 | |
| 0.027 | 0.017 | 0.027 | Calcium-sensing receptor agonist | |||
| 0.016 | 0.005 | 0.016 | Glutamate (mGluR6) agonist | |||
| 0.209 | 0.198 | 0.209 | Antiobesity | |||
| 0.043 | 0.032 | 0.043 | Dihydrofolate reductase inhibitor | |||
| 0.062 | 0.053 | 0.289 | Phosphodiesterase 4B inhibitor | 0.123 0.017 DBMET02629 0.289 0.005 DBMET02631 | DBMET02631 | |
| 0.118 | 0.109 | 0.257 | Dual specificity tyrosine-phosphorylation regulated kinase 1B inhibitor | 0.257 0.024 DBMET02629 0.213 0.036 DBMET02631 | DBMET02629 | |
| 0.096 | 0.088 | 0.11 | CDC-like kinase 3 inhibitor | 0.11 0.059 DBMET02629 0.102 0.075 DBMET02634 | DBMET02629 | |
| 0.061 | 0.053 | 0.074 | Beta adrenoreceptor antagonist | 0.074 0.033 DBMET02630 | DBMET02630 | |
| 0.023 | 0.015 | 0.023 | Bombesin agonist | |||
| 0.014 | 0.006 | 0.046 | Egl nine homolog 2 inhibitor | 0.046 0.004 DBMET02630 | DBMET02630 | |
| 0.057 | 0.05 | 0.057 | NMDA 2C receptor antagonist | |||
| 0.05 | 0.043 | 0.063 | Alpha-mannosidase inhibitor | 0.063 0.024 DBMET02630 0.049 0.047 DBMET02632 | DBMET02630 | |
| 0.052 | 0.045 | 0.067 | DNA helicase inhibitor | 0.067 0.02 DBMET02630 | DBMET02630 | |
| 0.011 | 0.004 | 0.011 | Mannitol 2-dehydrogenase inhibitor | |||
| 0.07 | 0.063 | 0.082 | Potassium channel (Tandem pore domain) blocker | 0.082 0.031 DBMET02629 0.081 0.032 DBMET02630 | DBMET02629 | |
| 0.028 | 0.021 | 0.041 | Purinergic P2Y15 antagonist | 0.041 0.006 DBMET02629 0.029 0.02 DBMET02630 0.03 0.018 DBMET02631 | DBMET02629 | |
| 0.027 | 0.02 | 0.027 | 11-Beta-hydroxysteroid dehydrogenase 2 inhibitor | |||
| 0.038 | 0.032 | 0.038 | Liver X receptor alpha agonist | |||
| 0.014 | 0.008 | 0.024 | 1-Deoxy-D-xylulose-5-phosphate reductoisomerase inhibitor | 0.024 0.004 DBMET02629 0.019 0.004 DBMET02630 0.015 0.007 DBMET02631 0.013 0.01 DBMET02634 | DBMET02629 | |
| 0.027 | 0.021 | 0.042 | Glucosylceramidase stimulant | 0.042 0.004 DBMET02629 0.029 0.015 DBMET02630 0.026 0.024 DBMET02632 | DBMET02629 | |
| 0.027 | 0.021 | 0.035 | Hedgehog signaling activator | 0.035 0.007 DBMET02629 | DBMET02629 | |
| 0.019 | 0.013 | 0.019 | Bombesin 3 receptor agonist | |||
| 0.037 | 0.032 | 0.07 | Toll-Like receptor 2 agonist | 0.07 0.018 DBMET02630 | DBMET02630 | |
| 0.032 | 0.027 | 0.032 | Purinergic P2Y2 antagonist | |||
| 0.019 | 0.014 | 0.019 | Steroid 17-alpha-hydroxylase/17,20 lyase inhibitor | |||
| 0.057 | 0.053 | 0.079 | 5 Hydroxytryptamine 3 agonist | 0.075 0.031 DBMET02629 0.079 0.027 DBMET02632 0.062 0.045 DBMET02633 0.057 0.054 DBMET02634 | DBMET02632 | |
| 0.082 | 0.078 | 0.136 | Prolactin inhibitor | 0.136 0.029 DBMET02632 0.093 0.063 DBMET02633 0.113 0.043 DBMET02634 | DBMET02632 | |
| 0.045 | 0.04 | 0.051 | Benzodiazepine antagonist | 0.051 0.024 DBMET02632 | DBMET02632 | |
| 0.099 | 0.095 | 0.16 | Interleukin 2 antagonist | 0.16 0.014 DBMET02629 0.12 0.045 DBMET02630 0.108 0.069 DBMET02634 | DBMET02629 | |
| 0.045 | 0.041 | 0.058 | Bombesin 2 receptor antagonist | 0.05 0.033 DBMET02629 0.058 0.025 DBMET02630 | DBMET02630 | |
| 0.039 | 0.035 | 0.039 | Sphingosine 1-phosphate receptor 1 agonist | |||
| 0.022 | 0.018 | 0.022 | Prostaglandin E2 agonist | |||
| 0.039 | 0.036 | 0.039 | NMDA receptor subunit 3B antagonist | |||
| 0.075 | 0.073 | 0.084 | GABA A receptor agonist | 0.084 0.057 DBMET02629 | DBMET02629 | |
| 0.022 | 0.02 | 0.022 | NMDA receptor glycine site antagonist | |||
| 0.075 | 0.072 | 0.075 | NMDA receptor antagonist | |||
| 0.017 | 0.015 | 0.023 | CXC chemokine 5 receptor antagonist | 0.023 0.005 DBMET02631 | DBMET02631 | |
| 0.03 | 0.029 | 0.03 | Protein kinase C beta II inhibitor | |||
| 0.035 | 0.034 | 0.043 | Potassium channel Kv1.1 blocker | 0.043 0.018 DBMET02629 | DBMET02629 | |
| 0.026 | 0.025 | 0.026 | Carnitine palmitoyltransferase 1A inhibitor | |||
| 0.018 | 0.017 | 0.018 | Peroxisome proliferator-activated receptor alpha antagonist | |||
| 0.023 | 0.022 | 0.023 | Lysophosphatidic acid receptor 1 agonist | |||
| 0.04 | 0.039 | 0.06 | Histamine H1 receptor agonist | 0.06 0.008 DBMET02629 0.044 0.03 DBMET02631 0.047 0.023 DBMET02632 0.044 0.029 DBMET02634 | DBMET02629 | |
| 0.079 | 0.078 | 0.089 | Phosphodiesterase I inhibitor | 0.089 0.059 DBMET02629 0.087 0.063 DBMET02634 | DBMET02629 | |
| 0.012 | 0.011 | 0.012 | Human herpes virus 5 capsid protein P40 inhibitor | |||
| 0.004 | 0.004 | 0.008 | Reverse transcriptase (HBV) inhibitor | 0.006 0.002 DBMET02629 0.008 0.002 DBMET02630 | DBMET02630 | |
| 0.006 | 0.006 | 0.01 | Integrin alpha5beta6 antagonist | 0.01 0.003 DBMET02630 | DBMET02630 | |
| 0.021 | 0.022 | 0.053 | Kainate receptor 4 antagonist | 0.053 0.006 DBMET02631 | DBMET02631 | |
| 0.077 | 0.078 | 0.095 | mTOR complex 2 inhibitor | 0.095 0.039 DBMET02629 0.083 0.06 DBMET02634 | DBMET02629 | |
| 0.107 | 0.109 | 0.127 | Protein kinase stimulant | 0.127 0.086 DBMET02632 | DBMET02632 | |
| 0.005 | 0.007 | 0.014 | CC chemokine 6 receptor agonist | 0.014 0.002 DBMET02629 0.006 0.005 DBMET02631 | DBMET02629 | |
| 0.094 | 0.097 | 0.546 | Histone deacetylase class III inhibitor | 0.546 0.004 DBMET02629 0.206 0.017 DBMET02630 0.258 0.009 DBMET02631 0.148 0.045 DBMET02633 0.265 0.008 DBMET02634 | DBMET02629 | |
| 0.063 | 0.066 | 0.13 | Nav1.8 sodium channel blocker | 0.13 0.018 DBMET02629 0.096 0.03 DBMET02634 | DBMET02629 | |
| 0.023 | 0.026 | 0.035 | Complement factor 1s inhibitor | 0.027 0.013 DBMET02629 0.035 0.005 DBMET02631 | DBMET02631 | |
| 0.106 | 0.11 | 0.413 | Histone deacetylase SIRT1 inhibitor | 0.413 0.004 DBMET02629 0.224 0.023 DBMET02630 0.259 0.015 DBMET02631 0.144 0.067 DBMET02633 0.252 0.017 DBMET02634 | DBMET02629 | |
| 0.061 | 0.065 | 0.504 | Phosphodiesterase 4D inhibitor | 0.092 0.04 DBMET02629 0.504 0.004 DBMET02631 | DBMET02631 | |
| 0.029 | 0.032 | 0.039 | Calcium release-activated channel blocker | 0.039 0.016 DBMET02629 | DBMET02629 | |
| 0.062 | 0.066 | 0.096 | Epoxide hydrolase inhibitor | 0.096 0.027 DBMET02630 | DBMET02630 | |
| 0.078 | 0.082 | 0.101 | Aminoacyl-tRNA synthetase inhibitor | 0.101 0.044 DBMET02629 0.083 0.072 DBMET02630 | DBMET02629 | |
| 0.014 | 0.019 | 0.03 | Cyclin T1 inhibitor | 0.03 0.005 DBMET02629 0.025 0.007 DBMET02631 | DBMET02629 | |
| 0.013 | 0.018 | 0.031 | Nicotinic alpha4 receptor agonist | 0.031 0.004 DBMET02629 0.021 0.007 DBMET02631 | DBMET02629 | |
| 0.056 | 0.061 | 0.078 | Aryl hydrocarbon receptor antagonist | 0.078 0.028 DBMET02629 | DBMET02629 | |
| 0.006 | 0.011 | 0.022 | Integrin alphaVbeta5 antagonist | 0.022 0.004 DBMET02630 | DBMET02630 | |
| 0.009 | 0.014 | 0.022 | Integrin beta2 antagonist | 0.022 0.005 DBMET02630 | DBMET02630 | |
| 0.13 | 0.135 | 0.202 | Interleukin antagonist | 0.202 0.083 DBMET02629 0.163 0.109 DBMET02630 | DBMET02629 | |
| 0.136 | 0.142 | 0.157 | Catenin beta inhibitor | 0.157 0.09 DBMET02632 | DBMET02632 | |
| 0.181 | 0.187 | 0.413 | Nootropic | 0.259 0.1 DBMET02629 0.196 0.163 DBMET02631 0.413 0.035 DBMET02632 0.185 0.179 DBMET02633 0.369 0.048 DBMET02634 | DBMET02632 | |
| 0.05 | 0.056 | 0.056 | Sphingosine 1-phosphate receptor 1 antagonist | 0.056 0.038 DBMET02630 | DBMET02630 | |
| 0.033 | 0.04 | 0.059 | Factor XIa inhibitor | 0.04 0.03 DBMET02631 0.059 0.013 DBMET02634 | DBMET02634 | |
| 0.043 | 0.051 | 0.118 | Protein kinase C epsilon inhibitor | 0.118 0.01 DBMET02629 | DBMET02629 | |
| 0.017 | 0.025 | 0.032 | Geranylgeranyltransferase inhibitor | 0.032 0.008 DBMET02632 0.031 0.009 DBMET02634 | DBMET02632 | |
| 0.01 | 0.019 | 0.023 | Integrin alphaVbeta6 antagonist | 0.023 0.005 DBMET02630 | DBMET02630 | |
| 0.114 | 0.124 | 0.343 | CDC-like kinase 2 inhibitor | 0.343 0.022 DBMET02629 0.123 0.116 DBMET02634 | DBMET02629 | |
| 0.043 | 0.053 | 0.05 | Nicotinic receptor alpha4 subunit antagonist | 0.05 0.033 DBMET02629 0.048 0.037 DBMET02632 | DBMET02629 | |
| 0.128 | 0.137 | 0.265 | Angiogenesis stimulant | 0.217 0.086 DBMET02630 0.265 0.063 DBMET02632 | DBMET02632 | |
| 0.035 | 0.045 | 0.041 | Nicotinic receptor alpha3 subunit antagonist | 0.039 0.036 DBMET02629 0.041 0.034 DBMET02632 | DBMET02632 | |
| 0.014 | 0.025 | 0.029 | Complement factor D inhibitor | 0.029 0.004 DBMET02629 0.024 0.005 DBMET02631 0.018 0.013 DBMET02634 | DBMET02629 | |
| 0.032 | 0.043 | 0.052 | MAP3K5 inhibitor | 0.052 0.011 DBMET02629 0.04 0.026 DBMET02633 | DBMET02629 | |
| 0.05 | 0.061 | 0.059 | Phosphodiesterase 1B inhibitor | 0.059 0.043 DBMET02629 | DBMET02629 | |
| 0.075 | 0.086 | 0.122 | Transforming growth factor beta 3 antagonist | 0.122 0.01 DBMET02629 0.08 0.065 DBMET02633 | DBMET02629 | |
| 0.034 | 0.046 | 0.071 | Histamine H2 receptor agonist | 0.071 0.01 DBMET02629 0.043 0.03 DBMET02631 | DBMET02629 | |
| 0.018 | 0.03 | 0.026 | Isoleucine-tRNA ligase inhibitor | 0.023 0.014 DBMET02629 0.022 0.017 DBMET02633 0.026 0.009 DBMET02634 | DBMET02634 | |
| 0.024 | 0.037 | 0.037 | Calcitonin receptor agonist | 0.037 0.022 DBMET02630 | DBMET02630 | |
| 0.01 | 0.024 | 0.017 | CXC chemokine 4 receptor agonist | 0.017 0.008 DBMET02629 | DBMET02629 | |
| 0.089 | 0.103 | 0.13 | Proteasome inhibitor | 0.098 0.09 DBMET02629 0.13 0.058 DBMET02630 | DBMET02630 | |
| 0.017 | 0.031 | 0.019 | Toll-Like receptor 8 agonist | 0.019 0.017 DBMET02629 | DBMET02629 | |
| 0.015 | 0.03 | 0.018 | Caspase 8 inhibitor | 0.018 0.016 DBMET02630 | DBMET02630 | |
| 0.028 | 0.043 | 0.036 | Ceramide glucosyltransferase inhibitor | 0.036 0.024 DBMET02630 | DBMET02630 | |
| 0.06 | 0.074 | 0.091 | Secretase beta inhibitor | 0.091 0.024 DBMET02629 0.066 0.058 DBMET02634 | DBMET02629 | |
| 0.058 | 0.074 | 0.144 | Rho-associated kinase I inhibitor | 0.144 0.015 DBMET02629 0.066 0.062 DBMET02631 | DBMET02629 | |
| 0.053 | 0.069 | 0.076 | Syk tyrosine kinase inhibitor | 0.076 0.044 DBMET02629 0.065 0.054 DBMET02633 0.07 0.05 DBMET02634 | DBMET02629 | |
| 0.074 | 0.091 | 0.148 | Pim-3 kinase inhibitor | 0.148 0.019 DBMET02629 | DBMET02629 | |
| 0.066 | 0.084 | 0.074 | Glycine receptor antagonist | 0.074 0.067 DBMET02632 | DBMET02632 | |
| 0.018 | 0.036 | 0.028 | CXC chemokine 2 receptor antagonist | 0.028 0.016 DBMET02629 0.028 0.015 DBMET02631 | DBMET02631 | |
| 0.027 | 0.045 | 0.053 | Factor XIIIa inhibitor | 0.049 0.016 DBMET02629 0.053 0.014 DBMET02630 0.049 0.016 DBMET02631 | DBMET02630 | |
| 0.012 | 0.031 | 0.021 | CDK2/cyclin A3 inhibitor | 0.021 0.005 DBMET02629 | DBMET02629 | |
| 0.039 | 0.058 | 0.093 | Benzodiazepine inverse agonist | 0.074 0.008 DBMET02629 0.093 0.005 DBMET02631 0.046 0.033 DBMET02633 0.055 0.019 DBMET02634 | DBMET02631 | |
| 0.045 | 0.064 | 0.074 | Epithelial sodium channel blocker | 0.074 0.015 DBMET02629 0.06 0.028 DBMET02630 0.052 0.044 DBMET02634 | DBMET02629 | |
| 0.034 | 0.053 | 0.049 | Glutamate (mGluR5) antagonist | 0.049 0.03 DBMET02629 | DBMET02629 | |
| 0.026 | 0.046 | 0.038 | Factor XI inhibitor | 0.038 0.018 DBMET02631 0.035 0.022 DBMET02634 | DBMET02631 | |
| 0.009 | 0.029 | 0.017 | 5-Alpha-reductase 1 inhibitor | 0.017 0.012 DBMET02634 | DBMET02634 | |
| 0.068 | 0.089 | 0.084 | Acetylcholine agonist | 0.084 0.061 DBMET02629 0.084 0.061 DBMET02632 0.081 0.065 DBMET02634 | DBMET02632 | |
| 0.047 | 0.068 | 0.089 | Cyclin D1 inhibitor | 0.086 0.014 DBMET02629 0.07 0.029 DBMET02632 0.083 0.016 DBMET02633 0.089 0.012 DBMET02634 | DBMET02634 | |
| 0.09 | 0.112 | 0.134 | Cholinergic antagonist | 0.134 0.062 DBMET02632 | DBMET02632 | |
| 0.06 | 0.082 | 0.068 | Adenosine A3 receptor antagonist | 0.068 0.062 DBMET02632 | DBMET02632 | |
| 0.089 | 0.112 | 0.254 | Activin receptor-like kinase 4 inhibitor | 0.254 0.007 DBMET02629 0.11 0.067 DBMET02634 | DBMET02629 | |
| 0.023 | 0.047 | 0.045 | 5-Alpha-reductase inhibitor | 0.037 0.026 DBMET02632 0.045 0.021 DBMET02634 | DBMET02634 | |
| 0.034 | 0.057 | 0.047 | VCAM-1 antagonist | 0.043 0.018 DBMET02629 0.047 0.012 DBMET02630 0.045 0.014 DBMET02631 | DBMET02630 | |
| 0.034 | 0.058 | 0.047 | VCAM antagonist | 0.043 0.018 DBMET02629 0.047 0.012 DBMET02630 0.045 0.015 DBMET02631 | DBMET02630 | |
| 0.073 | 0.097 | 0.185 | MAP kinase kinase kinase inhibitor | 0.171 0.027 DBMET02629 0.185 0.022 DBMET02631 0.089 0.077 DBMET02634 | DBMET02631 | |
| 0.024 | 0.049 | 0.031 | Dipeptidyl peptidase II inhibitor | 0.031 0.026 DBMET02634 | DBMET02634 | |
| 0.087 | 0.112 | 0.126 | Acetylcholine antagonist | 0.126 0.065 DBMET02632 | DBMET02632 | |
| 0.092 | 0.117 | 0.133 | Bone formation stimulant | 0.133 0.074 DBMET02630 | DBMET02630 | |
| 0.053 | 0.079 | 0.062 | Protein kinase C alpha inhibitor | 0.062 0.058 DBMET02629 | DBMET02629 | |
| 0.032 | 0.058 | 0.04 | Plasmepsin II inhibitor | 0.04 0.031 DBMET02629 | DBMET02629 | |
| 0.105 | 0.132 | 0.125 | Vanilloid 1 agonist | 0.125 0.075 DBMET02630 | DBMET02630 | |
| 0.054 | 0.081 | 0.107 | Benzodiazepine agonist | 0.088 0.033 DBMET02629 0.107 0.022 DBMET02631 0.072 0.048 DBMET02633 0.067 0.056 DBMET02634 | DBMET02631 | |
| 0.2 | 0.228 | 0.217 | Transcription factor inhibitor | 0.217 0.211 DBMET02629 | DBMET02629 | |
| 0.05 | 0.079 | 0.088 | Protease 3C (Human rhinovirus) inhibitor | 0.088 0.022 DBMET02629 0.073 0.034 DBMET02631 0.077 0.029 DBMET02633 0.076 0.031 DBMET02634 | DBMET02629 | |
| 0.07 | 0.099 | 0.348 | Bronchodilator | 0.348 0.007 DBMET02631 | DBMET02631 | |
| 0.097 | 0.127 | 0.183 | CDC-like kinase 1 inhibitor | 0.183 0.046 DBMET02629 | DBMET02629 | |
| 0.123 | 0.153 | 0.463 | Ca2+/calmodulin-dependent protein kinase inhibitor | 0.463 0.011 DBMET02629 0.139 0.123 DBMET02631 0.308 0.041 DBMET02633 0.213 0.069 DBMET02634 | DBMET02629 | |
| 0.076 | 0.106 | 0.099 | Nitric-oxide synthase inhibitor | 0.093 0.071 DBMET02629 0.099 0.062 DBMET02631 | DBMET02631 | |
| 0.043 | 0.074 | 0.057 | Sphingosine 1-phosphate receptor 5 agonist | 0.057 0.031 DBMET02630 | DBMET02630 | |
| 0.026 | 0.057 | 0.044 | Oxytocin agonist | 0.044 0.028 DBMET02629 0.037 0.036 DBMET02634 | DBMET02629 | |
| 0.035 | 0.067 | 0.051 | Potassium channel (Inward rectifier) blocker | 0.051 0.033 DBMET02629 | DBMET02629 | |
| 0.076 | 0.108 | 0.151 | Toll-Like receptor 3 antagonist | 0.151 0.014 DBMET02629 | DBMET02629 | |
| 0.005 | 0.039 | 0.015 | Integrin alpha4beta1 antagonist | 0.015 0.011 DBMET02630 | DBMET02630 | |
| 0.064 | 0.099 | 0.157 | Interleukin-1 receptor-associated protein kinase 4 inhibitor | 0.157 0.019 DBMET02629 0.086 0.061 DBMET02630 0.081 0.07 DBMET02631 0.094 0.052 DBMET02634 | DBMET02629 | |
| 0.065 | 0.101 | 0.109 | Histamine H2 receptor antagonist | 0.078 0.07 DBMET02629 0.109 0.027 DBMET02631 | DBMET02631 | |
| 0.048 | 0.084 | 0.065 | Enoyl-[acyl-carrier-protein] reductase inhibitor | 0.065 0.033 DBMET02629 0.061 0.041 DBMET02633 0.058 0.047 DBMET02634 | DBMET02629 | |
| 0.076 | 0.113 | 0.104 | Adenylate cyclase inhibitor | 0.104 0.081 DBMET02630 | DBMET02630 | |
| 0.038 | 0.075 | 0.08 | Pim-2 kinase inhibitor | 0.08 0.021 DBMET02629 | DBMET02629 | |
| 0.061 | 0.099 | 0.204 | I kappa B kinase inhibitor | 0.204 0.007 DBMET02629 0.087 0.051 DBMET02634 | DBMET02629 | |
| 0.061 | 0.099 | 0.07 | Vanilloid 4 agonist | 0.07 0.065 DBMET02632 | DBMET02632 | |
| 0.106 | 0.145 | 0.267 | CDC-like kinase 4 inhibitor | 0.267 0.04 DBMET02629 | DBMET02629 | |
| 0.072 | 0.11 | 0.147 | Cyclin-dependent kinase 9 inhibitor | 0.114 0.05 DBMET02629 0.147 0.035 DBMET02631 | DBMET02631 | |
| 0.013 | 0.051 | 0.033 | Integrin alphaVbeta3 antagonist | 0.033 0.007 DBMET02630 | DBMET02630 | |
| 0.025 | 0.064 | 0.049 | Transforming growth factor beta 2 antagonist | 0.049 0.007 DBMET02629 | DBMET02629 | |
| 0.057 | 0.096 | 0.145 | Protein kinase A inhibitor | 0.145 0.026 DBMET02629 | DBMET02629 | |
| 0.05 | 0.089 | 0.101 | Potassium channel large-conductance Ca-activated activator | 0.101 0.023 DBMET02631 | DBMET02631 | |
| 0.022 | 0.063 | 0.039 | Inosine monophosphate dehydrogenase inhibitor | 0.039 0.023 DBMET02629 0.033 0.029 DBMET02631 | DBMET02629 | |
| 0.052 | 0.093 | 0.109 | Protein kinase B beta inhibitor | 0.109 0.02 DBMET02629 0.078 0.044 DBMET02631 | DBMET02629 | |
| 0.095 | 0.136 | 0.22 | Activin receptor-like kinase 2 inhibitor | 0.22 0.029 DBMET02629 0.204 0.035 DBMET02634 | DBMET02629 | |
| 0.035 | 0.076 | 0.481 | Phosphodiesterase 4C inhibitor | 0.077 0.022 DBMET02629 0.481 0.003 DBMET02631 | DBMET02631 | |
| 0.041 | 0.082 | 0.07 | MAP kinase kinase 9 inhibitor | 0.07 0.021 DBMET02629 0.053 0.045 DBMET02634 | DBMET02629 | |
| 0.039 | 0.08 | 0.062 | Potassium channel Kv1.5 blocker | 0.062 0.035 DBMET02629 | DBMET02629 | |
| 0.041 | 0.085 | 0.053 | Angiotensin-converting enzyme inhibitor | 0.053 0.041 DBMET02630 | DBMET02630 | |
| 0.127 | 0.173 | 0.178 | Death-associated protein kinase 2 inhibitor | 0.178 0.057 DBMET02629 | DBMET02629 | |
| 0.18 | 0.227 | 0.204 | Interleukin 2 agonist | 0.204 0.182 DBMET02630 | DBMET02630 | |
| 0.067 | 0.114 | 0.092 | Thioredoxin reductase inhibitor | 0.092 0.038 DBMET02633 | DBMET02633 | |
| 0.043 | 0.091 | 0.099 | Heat shock protein 90 beta antagonist | 0.099 0.011 DBMET02629 0.054 0.052 DBMET02630 0.088 0.016 DBMET02633 0.069 0.029 DBMET02634 | DBMET02629 | |
| 0.04 | 0.088 | 0.063 | Acetylcholine M5 receptor agonist | 0.063 0.051 DBMET02632 | DBMET02632 | |
| 0.027 | 0.075 | 0.141 | Protein kinase (CK1) epsilon inhibitor | 0.141 0.003 DBMET02629 0.041 0.023 DBMET02631 0.04 0.026 DBMET02633 0.056 0.01 DBMET02634 | DBMET02629 | |
| 0.036 | 0.084 | 0.067 | Protein kinase C theta inhibitor | 0.067 0.026 DBMET02629 | DBMET02629 | |
| 0.089 | 0.138 | 0.27 | Protein kinase (CK1) gamma inhibitor | 0.27 0.025 DBMET02629 | DBMET02629 | |
| 0.011 | 0.06 | 0.085 | Nicotinamide phosphoribosyltransferase inhibitor | 0.085 0.008 DBMET02629 0.04 0.015 DBMET02630 | DBMET02629 | |
| 0.031 | 0.08 | 0.089 | Transforming growth factor beta 1 antagonist | 0.089 0.012 DBMET02629 0.051 0.033 DBMET02631 | DBMET02629 | |
| 0.162 | 0.211 | 0.372 | Ca2+/calmodulin-dependent kinase II alpha inhibitor | 0.372 0.029 DBMET02629 0.31 0.057 DBMET02632 0.32 0.051 DBMET02633 0.32 0.051 DBMET02634 | DBMET02629 | |
| 0.009 | 0.058 | 0.018 | Integrin beta6 antagonist | 0.018 0.005 DBMET02630 | DBMET02630 | |
| 0.021 | 0.07 | 0.032 | Histone deacetylase 7 inhibitor | 0.032 0.031 DBMET02630 | DBMET02630 | |
| 0.012 | 0.063 | 0.118 | Glucagon receptor antagonist | 0.118 0.004 DBMET02630 | DBMET02630 | |
| 0.027 | 0.078 | 0.043 | Histone deacetylase 9 inhibitor | 0.036 0.033 DBMET02630 0.043 0.021 DBMET02631 | DBMET02631 | |
| 0.021 | 0.073 | 0.048 | Vascular adhesion protein 1 inhibitor | 0.048 0.017 DBMET02629 0.047 0.018 DBMET02634 | DBMET02629 | |
| 0.018 | 0.071 | 0.028 | 5 Hydroxytryptamine 6 agonist | 0.028 0.021 DBMET02629 | DBMET02629 | |
| 0.012 | 0.065 | 0.017 | Tryptophan hydroxylase 1 inhibitor | 0.017 0.012 DBMET02630 | DBMET02630 | |
| 0.013 | 0.067 | 0.024 | Follicle-stimulating hormone antagonist | 0.019 0.015 DBMET02629 0.024 0.006 DBMET02631 | DBMET02631 | |
| 0.185 | 0.24 | 0.221 | DNA directed DNA polymerase inhibitor | 0.221 0.212 DBMET02634 | DBMET02634 | |
| 0.094 | 0.152 | 0.145 | Acetylcholine M1 receptor antagonist | 0.145 0.079 DBMET02632 0.12 0.109 DBMET02634 | DBMET02632 | |
| 0.016 | 0.073 | 0.027 | Peptide deformylase inhibitor | 0.027 0.024 DBMET02630 | DBMET02630 | |
| 0.023 | 0.081 | 0.06 | Integrin alpha5beta1 antagonist | 0.06 0.012 DBMET02630 | DBMET02630 | |
| 0.043 | 0.102 | 0.136 | I kappa B kinase 2 inhibitor | 0.136 0.006 DBMET02629 0.065 0.039 DBMET02634 | DBMET02629 | |
| 0.073 | 0.134 | 0.23 | Protein kinase (CK1) gamma 2 inhibitor | 0.23 0.024 DBMET02629 | DBMET02629 | |
| 0.047 | 0.108 | 0.233 | I kappa B kinase 1 inhibitor | 0.233 0.005 DBMET02629 0.073 0.044 DBMET02631 0.08 0.037 DBMET02634 | DBMET02629 | |
| 0.051 | 0.113 | 0.078 | Androgen antagonist | 0.078 0.068 DBMET02634 | DBMET02634 | |
| 0.017 | 0.079 | 0.041 | Carbonic anhydrase IV inhibitor | 0.041 0.032 DBMET02630 | DBMET02630 | |
| 0.03 | 0.092 | 0.072 | Toll-Like receptor 8 antagonist | 0.064 0.028 DBMET02629 0.072 0.022 DBMET02634 | DBMET02634 | |
| 0.029 | 0.093 | 0.148 | Farnesyltransferase inhibitor | 0.148 0.005 DBMET02631 | DBMET02631 | |
| 0.015 | 0.079 | 0.03 | CDK4/cyclin D3 inhibitor | 0.03 0.018 DBMET02629 | DBMET02629 | |
| 0.008 | 0.073 | 0.032 | Vitronectin receptor antagonist | 0.032 0.01 DBMET02630 | DBMET02630 | |
| 0.047 | 0.113 | 0.121 | Transforming growth factor antagonist | 0.121 0.013 DBMET02629 0.071 0.046 DBMET02631 | DBMET02629 | |
| 0.024 | 0.089 | 0.591 | Phosphodiesterase 4A inhibitor | 0.045 0.039 DBMET02629 0.591 0.003 DBMET02631 | DBMET02631 | |
| 0.067 | 0.133 | 0.171 | 5 Hydroxytryptamine 3A agonist | 0.141 0.041 DBMET02629 0.13 0.048 DBMET02632 0.171 0.025 DBMET02633 0.148 0.037 DBMET02634 | DBMET02633 | |
| 0.03 | 0.096 | 0.05 | GABA receptor antagonist | 0.05 0.044 DBMET02632 | DBMET02632 | |
| 0.032 | 0.098 | 0.052 | Dipeptidyl peptidase IV inhibitor | 0.041 0.039 DBMET02629 0.052 0.018 DBMET02634 | DBMET02634 | |
| 0.015 | 0.082 | 0.097 | Integrin antagonist | 0.097 0.017 DBMET02630 | DBMET02630 | |
| 0.035 | 0.102 | 0.092 | Protein kinase C iota inhibitor | 0.092 0.021 DBMET02629 | DBMET02629 | |
| 0.009 | 0.078 | 0.036 | 5 Hydroxytryptamine 1D agonist | 0.036 0.016 DBMET02629 0.034 0.017 DBMET02634 | DBMET02629 | |
| 0.005 | 0.074 | 0.024 | Integrin alpha4 antagonist | 0.024 0.018 DBMET02630 | DBMET02630 | |
| 0.005 | 0.075 | 0.026 | VLA-4 antagonist | 0.026 0.018 DBMET02630 | DBMET02630 | |
| 0.117 | 0.188 | 0.34 | Ca2+/calmodulin-dependent kinase II beta inhibitor | 0.317 0.032 DBMET02629 0.34 0.025 DBMET02633 0.155 0.122 DBMET02634 | DBMET02633 | |
| 0.016 | 0.087 | 0.026 | Thrombin receptor antagonist | 0.026 0.023 DBMET02629 | DBMET02629 | |
| 0.067 | 0.138 | 0.09 | CC chemokine 5 receptor agonist | 0.09 0.037 DBMET02631 | DBMET02631 | |
| 0.09 | 0.161 | 0.214 | Anticoagulant | 0.138 0.091 DBMET02629 0.214 0.048 DBMET02630 0.161 0.072 DBMET02631 0.139 0.09 DBMET02634 | DBMET02630 | |
| 0.021 | 0.094 | 0.042 | Delayed rectifier potassium channel blocker | 0.042 0.019 DBMET02629 0.034 0.032 DBMET02634 | DBMET02629 | |
| 0.062 | 0.135 | 0.109 | Glycogen synthase kinase-3 beta inhibitor | 0.109 0.069 DBMET02629 0.103 0.074 DBMET02634 | DBMET02629 | |
| 0.098 | 0.174 | 0.312 | Clk dual-specificity kinase inhibitor | 0.312 0.036 DBMET02629 | DBMET02629 | |
| 0.027 | 0.103 | 0.089 | Nicotinic neuronal receptor agonist | 0.089 0.017 DBMET02629 0.062 0.034 DBMET02631 0.055 0.04 DBMET02634 | DBMET02629 | |
| 0.04 | 0.116 | 0.194 | Rho-associated kinase inhibitor | 0.194 0.013 DBMET02629 | DBMET02629 | |
| 0.021 | 0.097 | 0.034 | ATR kinase inhibitor | 0.034 0.021 DBMET02629 | DBMET02629 | |
| 0.029 | 0.105 | 0.051 | H+/K+-transporting ATPase inhibitor | 0.05 0.037 DBMET02629 0.051 0.035 DBMET02631 | DBMET02631 | |
| 0.054 | 0.131 | 0.087 | 5-Lipoxygenase inhibitor | 0.087 0.074 DBMET02631 | DBMET02631 | |
| 0.045 | 0.121 | 0.073 | MAP-kinase-activated kinase 2 inhibitor | 0.073 0.053 DBMET02629 | DBMET02629 | |
| 0.083 | 0.159 | 0.333 | Protein kinase C nu inhibitor | 0.333 0.018 DBMET02629 | DBMET02629 | |
| 0.028 | 0.106 | 0.041 | Integrin alpha1beta1 antagonist | 0.041 0.019 DBMET02630 | DBMET02630 | |
| 0.012 | 0.091 | 0.021 | Factor XIII inhibitor | 0.021 0.013 DBMET02629 | DBMET02629 | |
| 0.005 | 0.085 | 0.022 | Integrin alpha4beta7 antagonist | 0.022 0.013 DBMET02630 | DBMET02630 | |
| 0.028 | 0.109 | 0.049 | Cathepsin F inhibitor | 0.049 0.014 DBMET02631 | DBMET02631 | |
| 0.009 | 0.091 | 0.029 | Integrin alphaVbeta1 antagonist | 0.029 0.006 DBMET02630 | DBMET02630 | |
| 0.03 | 0.113 | 0.075 | Cyclin A1 inhibitor | 0.068 0.025 DBMET02629 0.074 0.018 DBMET02631 0.075 0.017 DBMET02634 | DBMET02634 | |
| 0.014 | 0.099 | 0.029 | Acid ceramidase inhibitor | 0.029 0.011 DBMET02632 0.025 0.019 DBMET02634 | DBMET02632 | |
| 0.053 | 0.137 | 0.155 | Vascular endothelial growth factor 1 antagonist | 0.155 0.039 DBMET02629 | DBMET02629 | |
| 0.055 | 0.14 | 0.104 | Antihistaminic | 0.104 0.052 DBMET02631 | DBMET02631 | |
| 0.05 | 0.135 | 0.091 | MAP-kinase-activated kinase inhibitor | 0.091 0.048 DBMET02629 | DBMET02629 | |
| 0.009 | 0.094 | 0.049 | Cyclin E2 inhibitor | 0.028 0.021 DBMET02629 0.049 0.009 DBMET02633 0.026 0.022 DBMET02634 | DBMET02633 | |
| 0.028 | 0.114 | 0.083 | Nicotinic alpha7 receptor agonist | 0.083 0.017 DBMET02629 0.057 0.035 DBMET02634 | DBMET02629 | |
| 0.068 | 0.155 | 0.099 | Multidrug resistance-associated protein 1 inhibitor | 0.099 0.08 DBMET02629 0.095 0.087 DBMET02630 | DBMET02629 | |
| 0.079 | 0.166 | 0.143 | Toll-Like receptor antagonist | 0.132 0.07 DBMET02632 0.143 0.061 DBMET02634 | DBMET02634 | |
| 0.058 | 0.146 | 0.108 | Glycogen synthase kinase-3 inhibitor | 0.108 0.072 DBMET02629 0.097 0.082 DBMET02634 | DBMET02629 | |
| 0.066 | 0.156 | 0.188 | TRKA antagonist | 0.188 0.034 DBMET02629 0.169 0.04 DBMET02634 | DBMET02629 | |
| 0.013 | 0.105 | 0.044 | 5 Hydroxytryptamine 3B antagonist | 0.044 0.018 DBMET02632 | DBMET02632 | |
| 0.038 | 0.13 | 0.542 | Histone deacetylase SIRT2 inhibitor | 0.542 0.003 DBMET02629 0.124 0.014 DBMET02630 0.248 0.004 DBMET02631 0.085 0.041 DBMET02633 0.242 0.004 DBMET02634 | DBMET02629 | |
| 0.045 | 0.138 | 0.126 | MAP kinase kinase 8 inhibitor | 0.126 0.013 DBMET02629 0.104 0.02 DBMET02634 | DBMET02629 | |
| 0.007 | 0.1 | 0.049 | CXC chemokine receptor agonist | 0.047 0.005 DBMET02629 0.049 0.005 DBMET02631 | DBMET02631 | |
| 0.103 | 0.197 | 0.277 | Anticonvulsant | 0.157 0.121 DBMET02629 0.147 0.133 DBMET02630 0.277 0.047 DBMET02631 0.151 0.128 DBMET02632 0.176 0.102 DBMET02634 | DBMET02631 | |
| 0.039 | 0.134 | 0.066 | Corticotropin releasing factor 2 receptor antagonist | 0.066 0.034 DBMET02629 0.066 0.035 DBMET02634 | DBMET02634 | |
| 0.088 | 0.184 | 0.273 | Interleukin-1 receptor-associated protein kinase 1 inhibitor | 0.273 0.04 DBMET02629 0.145 0.099 DBMET02633 | DBMET02629 | |
| 0.029 | 0.125 | 0.101 | Cyclin A2 inhibitor | 0.09 0.028 DBMET02629 0.101 0.024 DBMET02631 0.094 0.027 DBMET02634 | DBMET02631 | |
| 0.033 | 0.13 | 0.064 | Dipeptidyl peptidase inhibitor | 0.048 0.046 DBMET02629 0.064 0.022 DBMET02634 | DBMET02634 | |
| 0.072 | 0.17 | 0.304 | Ca2+/calmodulin-dependent kinase II delta inhibitor | 0.304 0.018 DBMET02629 0.236 0.036 DBMET02633 0.127 0.079 DBMET02634 | DBMET02629 | |
| 0.008 | 0.108 | 0.02 | O6-alkylguanine-DNA alkyltransferase inhibitor | 0.02 0.006 DBMET02631 | DBMET02631 | |
| 0.078 | 0.179 | 0.383 | Ca2+/calmodulin-dependent kinase II gamma inhibitor | 0.383 0.02 DBMET02629 0.381 0.021 DBMET02633 0.174 0.076 DBMET02634 | DBMET02629 | |
| 0.024 | 0.126 | 0.063 | 5 Hydroxytryptamine 4 antagonist | 0.063 0.021 DBMET02632 | DBMET02632 | |
| 0.091 | 0.195 | 0.256 | Polo-like kinase-3 inhibitor | 0.256 0.022 DBMET02629 0.189 0.051 DBMET02633 0.161 0.073 DBMET02634 | DBMET02629 | |
| 0.005 | 0.11 | 0.035 | Growth hormone releasing factor antagonist | 0.035 0.011 DBMET02631 | DBMET02631 | |
| 0.017 | 0.122 | 0.091 | Chemokine receptor agonist | 0.085 0.006 DBMET02629 0.091 0.005 DBMET02631 | DBMET02631 | |
| 0.026 | 0.133 | 0.092 | Cyclin A inhibitor | 0.085 0.029 DBMET02629 0.092 0.026 DBMET02631 0.085 0.029 DBMET02634 | DBMET02631 | |
| 0.042 | 0.149 | 0.095 | Histamine antagonist | 0.095 0.051 DBMET02631 | DBMET02631 | |
| 0.026 | 0.133 | 0.059 | Glucagon-like peptide 1 agonist | 0.059 0.049 DBMET02630 | DBMET02630 | |
| 0.008 | 0.115 | 0.064 | GP IIb/IIIa receptor antagonist | 0.064 0.026 DBMET02630 | DBMET02630 | |
| 0.05 | 0.157 | 0.208 | Granulocyte macrophage colony stimulating factor antagonist | 0.208 0.02 DBMET02629 0.192 0.024 DBMET02631 0.131 0.046 DBMET02633 0.163 0.032 DBMET02634 | DBMET02629 | |
| 0.059 | 0.167 | 0.142 | MAP kinase 13 inhibitor | 0.142 0.04 DBMET02629 | DBMET02629 | |
| 0.165 | 0.274 | 0.297 | Ca(v)3.3 blocker | 0.297 0.044 DBMET02629 0.229 0.135 DBMET02630 | DBMET02629 | |
| 0.068 | 0.178 | 0.154 | Lipid peroxidase inhibitor | 0.154 0.066 DBMET02632 | DBMET02632 | |
| 0.06 | 0.171 | 0.132 | MAP kinase 12 inhibitor | 0.132 0.056 DBMET02629 | DBMET02629 | |
| 0.06 | 0.171 | 0.102 | Nav1.3 sodium channel blocker | 0.102 0.095 DBMET02629 | DBMET02629 | |
| 0.009 | 0.122 | 0.054 | Plasma kallikrein inhibitor | 0.038 0.02 DBMET02629 0.053 0.011 DBMET02631 0.054 0.01 DBMET02634 | DBMET02634 | |
| 0.168 | 0.281 | 0.282 | Ca2+/calmodulin-dependent kinase IV inhibitor | 0.282 0.035 DBMET02629 0.215 0.126 DBMET02634 | DBMET02629 | |
| 0.018 | 0.134 | 0.05 | Acetylcholine muscarinic agonist | 0.05 0.043 DBMET02632 | DBMET02632 | |
| 0.028 | 0.144 | 0.09 | 5 Hydroxytryptamine 3A antagonist | 0.062 0.053 DBMET02629 0.085 0.026 DBMET02632 0.09 0.022 DBMET02634 | DBMET02634 | |
| 0.026 | 0.143 | 0.07 | CXC chemokine 4 receptor antagonist | 0.07 0.036 DBMET02629 0.055 0.046 DBMET02631 | DBMET02629 | |
| 0.039 | 0.156 | 0.067 | Caspase 9 inhibitor | 0.067 0.036 DBMET02630 | DBMET02630 | |
| 0.028 | 0.146 | 0.085 | CXC chemokine 1 receptor antagonist | 0.082 0.008 DBMET02629 0.051 0.035 DBMET02630 0.085 0.007 DBMET02631 0.067 0.014 DBMET02634 | DBMET02631 | |
| 0.062 | 0.181 | 0.176 | Tyrosine-protein kinase receptor antagonist | 0.176 0.051 DBMET02629 0.165 0.056 DBMET02634 | DBMET02629 | |
| 0.026 | 0.146 | 0.068 | Lysine-specific demethylase 1A inhibitor | 0.052 0.04 DBMET02629 0.068 0.019 DBMET02634 | DBMET02634 | |
| 0.009 | 0.129 | 0.037 | Sirtuin 2 inhibitor | 0.037 0.02 DBMET02629 | DBMET02629 | |
| 0.07 | 0.19 | 0.111 | CDK3/cyclin E inhibitor | 0.111 0.068 DBMET02630 | DBMET02630 | |
| 0.137 | 0.259 | 0.405 | Angiogenesis inhibitor | 0.318 0.084 DBMET02629 0.219 0.149 DBMET02631 0.405 0.052 DBMET02633 | DBMET02633 | |
| 0.012 | 0.136 | 0.037 | Acetylcholine M1 receptor agonist | 0.037 0.035 DBMET02632 | DBMET02632 | |
| 0.066 | 0.19 | 0.155 | Nav1.5 sodium channel blocker | 0.155 0.024 DBMET02629 0.112 0.065 DBMET02634 | DBMET02629 | |
| 0.163 | 0.288 | 0.274 | Analgesic | 0.274 0.162 DBMET02632 | DBMET02632 | |
| 0.068 | 0.194 | 0.194 | Nav1.2 sodium channel blocker | 0.194 0.037 DBMET02629 0.112 0.093 DBMET02630 0.109 0.097 DBMET02634 | DBMET02629 | |
| 0.022 | 0.149 | 0.034 | Adenosine uptake inhibitor | 0.034 0.027 DBMET02634 | DBMET02634 | |
| 0.031 | 0.159 | 0.056 | 5 Hydroxytryptamine 7 agonist | 0.056 0.039 DBMET02629 0.052 0.048 DBMET02634 | DBMET02629 | |
| 0.048 | 0.177 | 0.186 | MAP kinase 8 inhibitor | 0.186 0.019 DBMET02629 0.106 0.054 DBMET02634 | DBMET02629 | |
| 0.022 | 0.151 | 0.069 | Adenosine A2 receptor antagonist | 0.069 0.041 DBMET02634 | DBMET02634 | |
| 0.034 | 0.164 | 0.113 | MAP kinase 10 inhibitor | 0.113 0.028 DBMET02629 | DBMET02629 | |
| 0.044 | 0.179 | 0.098 | Cyclin-dependent kinase 5 inhibitor | 0.098 0.077 DBMET02629 | DBMET02629 | |
| 0.017 | 0.155 | 0.079 | Cannabinoid CB1 receptor agonist | 0.079 0.029 DBMET02631 | DBMET02631 | |
| 0.01 | 0.149 | 0.063 | Factor Xa inhibitor | 0.063 0.023 DBMET02631 | DBMET02631 | |
| 0.019 | 0.159 | 0.063 | Kallikrein inhibitor | 0.044 0.036 DBMET02629 0.059 0.024 DBMET02631 0.063 0.022 DBMET02634 | DBMET02634 | |
| 0.132 | 0.273 | 0.31 | Immunomodulator | 0.287 0.09 DBMET02633 0.31 0.077 DBMET02634 | DBMET02634 | |
| 0.044 | 0.186 | 0.155 | MAP kinase 9 inhibitor | 0.155 0.036 DBMET02629 | DBMET02629 | |
| 0.046 | 0.188 | 0.104 | Aurora-B kinase inhibitor | 0.104 0.078 DBMET02629 | DBMET02629 | |
| 0.03 | 0.174 | 0.105 | Nav1.7 sodium channel blocker | 0.105 0.021 DBMET02629 0.069 0.045 DBMET02634 | DBMET02629 | |
| 0.048 | 0.194 | 0.377 | Protein kinase (CK1) inhibitor | 0.377 0.01 DBMET02629 0.142 0.074 DBMET02634 | DBMET02629 | |
| 0.033 | 0.18 | 0.189 | Rho-associated kinase II inhibitor | 0.189 0.013 DBMET02629 | DBMET02629 | |
| 0.087 | 0.238 | 0.144 | Interleukin 6 antagonist | 0.144 0.099 DBMET02629 | DBMET02629 | |
| 0.053 | 0.206 | 0.183 | Ribosomal protein S6 kinase inhibitor | 0.183 0.045 DBMET02629 | DBMET02629 | |
| 0.028 | 0.183 | 0.077 | Leucine-rich repeat kinase 2 inhibitor | 0.077 0.06 DBMET02629 | DBMET02629 | |
| 0.027 | 0.182 | 0.115 | Histone deacetylase inhibitor | 0.115 0.014 DBMET02629 0.067 0.043 DBMET02630 0.065 0.046 DBMET02631 0.069 0.041 DBMET02634 | DBMET02629 | |
| 0.015 | 0.17 | 0.063 | Adenosine A2a receptor antagonist | 0.063 0.042 DBMET02634 | DBMET02634 | |
| 0.043 | 0.199 | 0.189 | Protein kinase C mu inhibitor | 0.189 0.014 DBMET02629 0.106 0.051 DBMET02634 | DBMET02629 | |
| 0.034 | 0.19 | 0.193 | Stem cell growth factor agonist | 0.193 0.011 DBMET02629 0.075 0.072 DBMET02630 0.08 0.066 DBMET02631 | DBMET02629 | |
| 0.046 | 0.204 | 0.115 | Insulin receptor antagonist | 0.115 0.046 DBMET02629 0.104 0.056 DBMET02633 | DBMET02629 | |
| 0.011 | 0.173 | 0.043 | CDK6/cyclin D3 inhibitor | 0.043 0.011 DBMET02634 | DBMET02634 | |
| 0.047 | 0.209 | 0.076 | Factor XII inhibitor | 0.076 0.074 DBMET02631 | DBMET02631 | |
| 0.053 | 0.216 | 0.253 | Cyclin-dependent kinase 7 inhibitor | 0.253 0.02 DBMET02629 0.218 0.028 DBMET02631 | DBMET02629 | |
| 0.123 | 0.286 | 0.251 | MAP kinase kinase 5 inhibitor | 0.251 0.006 DBMET02629 0.19 0.045 DBMET02631 0.191 0.044 DBMET02633 0.196 0.037 DBMET02634 | DBMET02629 | |
| 0.039 | 0.203 | 0.317 | Platelet activating factor antagonist | 0.317 0.01 DBMET02631 0.107 0.073 DBMET02633 | DBMET02631 | |
| 0.013 | 0.177 | 0.105 | Glycine transporter 2 inhibitor | 0.105 0.012 DBMET02630 | DBMET02630 | |
| 0.054 | 0.22 | 0.191 | Sodium channel (voltage-gated) blocker | 0.191 0.033 DBMET02629 0.156 0.05 DBMET02634 | DBMET02629 | |
| 0.036 | 0.208 | 0.117 | MAO inhibitor | 0.107 0.084 DBMET02632 0.117 0.076 DBMET02633 | DBMET02633 | |
| 0.029 | 0.202 | 0.086 | MAO A inhibitor | 0.086 0.075 DBMET02632 | DBMET02632 | |
| 0.048 | 0.222 | 0.111 | DNA directed RNA polymerase inhibitor | 0.111 0.045 DBMET02631 | DBMET02631 | |
| 0.024 | 0.2 | 0.062 | CDK2/cyclin E2 inhibitor | 0.062 0.06 DBMET02629 | DBMET02629 | |
| 0.028 | 0.205 | 0.053 | 5 Hydroxytryptamine 5 antagonist | 0.053 0.05 DBMET02634 | DBMET02634 | |
| 0.024 | 0.201 | 0.222 | CXC chemokine receptor antagonist | 0.099 0.025 DBMET02629 0.222 0.005 DBMET02631 | DBMET02631 | |
| 0.16 | 0.339 | 0.286 | Apoptosis agonist | 0.286 0.183 DBMET02632 | DBMET02632 | |
| 0.031 | 0.21 | 0.06 | 5 Hydroxytryptamine 5A antagonist | 0.06 0.045 DBMET02634 | DBMET02634 | |
| 0.037 | 0.217 | 0.122 | Polo-like kinase-4 inhibitor | 0.122 0.055 DBMET02629 | DBMET02629 | |
| 0.027 | 0.21 | 0.07 | Sodium/calcium exchanger inhibitor | 0.07 0.012 DBMET02629 0.05 0.034 DBMET02630 0.053 0.028 DBMET02634 | DBMET02629 | |
| 0.009 | 0.192 | 0.047 | Glycine transporter inhibitor | 0.047 0.034 DBMET02630 | DBMET02630 | |
| 0.026 | 0.219 | 0.061 | Cyclin B3 inhibitor | 0.061 0.054 DBMET02634 | DBMET02634 | |
| 0.005 | 0.197 | 0.028 | Follicle-stimulating hormone agonist | 0.022 0.016 DBMET02629 0.028 0.011 DBMET02631 | DBMET02631 | |
| 0.026 | 0.22 | 0.118 | MAP3K7 inhibitor | 0.118 0.014 DBMET02629 0.098 0.023 DBMET02633 0.075 0.047 DBMET02634 | DBMET02629 | |
| 0.048 | 0.244 | 0.57 | Phosphodiesterase inhibitor | 0.57 0.005 DBMET02631 | DBMET02631 | |
| 0.015 | 0.21 | 0.062 | Cannabinoid receptor agonist | 0.062 0.047 DBMET02631 | DBMET02631 | |
| 0.029 | 0.225 | 0.217 | Protein kinase (CK1) delta inhibitor | 0.217 0.024 DBMET02629 | DBMET02629 | |
| 0.026 | 0.223 | 0.078 | Protein kinase (Mos, Mil/Raf, MEKK, RIPK, TESK, LIMK, IRAK, ILK, Activin/TGF-beta) inhibitor | 0.078 0.074 DBMET02629 | DBMET02629 | |
| 0.017 | 0.216 | 0.062 | 5 Hydroxytryptamine 3 antagonist | 0.062 0.034 DBMET02632 0.062 0.034 DBMET02634 | DBMET02634 | |
| 0.081 | 0.283 | 0.653 | Tumour necrosis factor alpha release inhibitor | 0.172 0.133 DBMET02629 0.653 0.005 DBMET02631 | DBMET02631 | |
| 0.13 | 0.338 | 0.279 | Caspase 3 stimulant | 0.279 0.091 DBMET02632 | DBMET02632 | |
| 0.013 | 0.228 | 0.124 | Bromodomain-containing protein 3 inhibitor | 0.124 0.004 DBMET02634 | DBMET02634 | |
| 0.1 | 0.315 | 0.282 | MAP-kinase-activated kinase 5 inhibitor | 0.282 0.04 DBMET02629 0.217 0.084 DBMET02634 | DBMET02629 | |
| 0.027 | 0.242 | 0.109 | Protein kinase B alpha inhibitor | 0.109 0.025 DBMET02629 | DBMET02629 | |
| 0.024 | 0.244 | 0.064 | Sirtuin 1 inhibitor | 0.064 0.052 DBMET02629 | DBMET02629 | |
| 0.039 | 0.259 | 0.114 | Cyclin-dependent kinase inhibitor | 0.114 0.078 DBMET02629 | DBMET02629 | |
| 0.02 | 0.243 | 0.105 | Check point kinase 1 inhibitor | 0.105 0.026 DBMET02629 | DBMET02629 | |
| 0.017 | 0.244 | 0.081 | 5 Hydroxytryptamine 2A agonist | 0.081 0.027 DBMET02634 | DBMET02634 | |
| 0.028 | 0.262 | 0.114 | Cyclin-dependent kinase 2 inhibitor | 0.114 0.057 DBMET02629 0.094 0.076 DBMET02631 | DBMET02629 | |
| 0.007 | 0.246 | 0.015 | CC chemokine 10 receptor antagonist | 0.015 0.012 DBMET02631 | DBMET02631 | |
| 0.031 | 0.27 | 0.057 | Kallikrein 1 inhibitor | 0.057 0.038 DBMET02629 0.052 0.049 DBMET02634 | DBMET02629 | |
| 0.075 | 0.315 | 0.352 | Ca2+/calmodulin-dependent kinase I alpha inhibitor | 0.352 0.024 DBMET02629 | DBMET02629 | |
| 0.029 | 0.269 | 0.228 | Protein-tyrosine kinase (PTK, not ETK, WZC) inhibitor | 0.228 0.021 DBMET02629 0.125 0.064 DBMET02631 | DBMET02629 | |
| 0.04 | 0.281 | 0.174 | Toll-Like receptor 9 antagonist | 0.162 0.056 DBMET02632 0.174 0.049 DBMET02634 | DBMET02634 | |
| 0.013 | 0.254 | 0.106 | Janus tyrosine kinase 3 inhibitor | 0.106 0.031 DBMET02629 | DBMET02629 | |
| 0.018 | 0.26 | 0.241 | Protein kinase (CaMK, MLCK, PhK, SNF, KIN, NIM1, MAPKAP, POLO, CHK, ULK, RSK-2nd domain) inhibitor | 0.241 0.01 DBMET02629 0.092 0.041 DBMET02631 0.07 0.061 DBMET02634 | DBMET02629 | |
| 0.028 | 0.271 | 0.228 | Abl kinase inhibitor | 0.228 0.021 DBMET02629 0.125 0.064 DBMET02631 | DBMET02629 | |
| 0.022 | 0.266 | 0.401 | Check point kinase 2 inhibitor | 0.401 0.004 DBMET02629 0.249 0.01 DBMET02631 0.163 0.028 DBMET02633 0.231 0.012 DBMET02634 | DBMET02629 | |
| 0.05 | 0.297 | 0.098 | Hedgehog signaling inhibitor | 0.098 0.069 DBMET02629 | DBMET02629 | |
| 0.042 | 0.289 | 0.188 | Sodium channel blocker | 0.188 0.037 DBMET02629 0.144 0.062 DBMET02634 | DBMET02629 | |
| 0.013 | 0.266 | 0.03 | DNA polymerase III inhibitor | 0.03 0.015 DBMET02634 | DBMET02634 | |
| 0.01 | 0.269 | 0.044 | 11-Beta-hydroxysteroid dehydrogenase 1 inhibitor | 0.044 0.036 DBMET02634 | DBMET02634 | |
| 0.018 | 0.279 | 0.051 | Human rhinovirus A protease inhibitor | 0.051 0.042 DBMET02629 | DBMET02629 | |
| 0.017 | 0.282 | 0.082 | MAP kinase 11 inhibitor | 0.082 0.046 DBMET02629 0.068 0.057 DBMET02631 | DBMET02629 | |
| 0.014 | 0.28 | 0.096 | MAP kinase 14 inhibitor | 0.096 0.038 DBMET02631 | DBMET02631 | |
| 0.029 | 0.297 | 0.257 | DNA intercalator | 0.257 0.015 DBMET02632 0.106 0.068 DBMET02633 | DBMET02632 | |
| 0.031 | 0.302 | 0.055 | Gonadotropin-releasing hormone receptor agonist | 0.055 0.053 DBMET02630 | DBMET02630 | |
| 0.009 | 0.284 | 0.073 | Tyrosine-protein kinase EMT inhibitor | 0.073 0.029 DBMET02629 | DBMET02629 | |
| 0.049 | 0.328 | 0.085 | T cell inhibitor | 0.085 0.05 DBMET02630 | DBMET02630 | |
| 0.012 | 0.292 | 0.067 | Plasminogen activator inhibitor | 0.067 0.034 DBMET02631 | DBMET02631 | |
| 0.012 | 0.303 | 0.08 | 5 Hydroxytryptamine 1D antagonist | 0.08 0.031 DBMET02634 | DBMET02634 | |
| 0.023 | 0.316 | 0.113 | RET inhibitor | 0.113 0.084 DBMET02629 | DBMET02629 | |
| 0.045 | 0.342 | 0.271 | TRKC antagonist | 0.271 0.04 DBMET02629 0.236 0.053 DBMET02633 0.163 0.091 DBMET02634 | DBMET02629 | |
| 0.007 | 0.311 | 0.038 | Cyclin D3 inhibitor | 0.038 0.028 DBMET02634 | DBMET02634 | |
| 0.005 | 0.319 | 0.048 | 5 Hydroxytryptamine 2 agonist | 0.048 0.04 DBMET02634 | DBMET02634 | |
| 0.019 | 0.335 | 0.318 | Chemokine receptor antagonist | 0.318 0.006 DBMET02631 | DBMET02631 | |
| 0.008 | 0.33 | 0.118 | Tyk2 inhibitor | 0.118 0.021 DBMET02629 | DBMET02629 | |
| 0.036 | 0.359 | 0.059 | Prolactin release inhibitor | 0.059 0.055 DBMET02634 | DBMET02634 | |
| 0.015 | 0.338 | 0.184 | Janus tyrosine kinase 2 inhibitor | 0.184 0.014 DBMET02629 | DBMET02629 | |
| 0.009 | 0.334 | 0.43 | Macrophage colony-stimulating factor 1 receptor antagonist | 0.233 0.006 DBMET02629 0.191 0.009 DBMET02631 0.43 0.004 DBMET02633 0.135 0.018 DBMET02634 | DBMET02633 | |
| 0.016 | 0.34 | 0.049 | ATM kinase inhibitor | 0.049 0.009 DBMET02629 0.041 0.016 DBMET02634 | DBMET02629 | |
| 0.063 | 0.388 | 0.144 | Sphingosine 1-phosphate receptor 2 agonist | 0.144 0.029 DBMET02632 0.133 0.039 DBMET02634 | DBMET02632 | |
| 0.011 | 0.34 | 0.131 | p38 MAP kinase inhibitor | 0.131 0.023 DBMET02631 | DBMET02631 | |
| 0.018 | 0.353 | 0.139 | CDK2/cyclin A inhibitor | 0.097 0.06 DBMET02629 0.089 0.068 DBMET02631 0.139 0.031 DBMET02634 | DBMET02634 | |
| 0.024 | 0.361 | 0.144 | Vascular endothelial growth factor 3 antagonist | 0.139 0.076 DBMET02629 0.144 0.071 DBMET02633 | DBMET02633 | |
| 0.03 | 0.372 | 0.13 | Src kinase inhibitor | 0.13 0.099 DBMET02629 | DBMET02629 | |
| 0.038 | 0.386 | 0.076 | MAP kinase 7 inhibitor | 0.074 0.068 DBMET02629 0.076 0.058 DBMET02634 | DBMET02634 | |
| 0.013 | 0.365 | 0.184 | CC chemokine receptor antagonist | 0.184 0.013 DBMET02631 | DBMET02631 | |
| 0.014 | 0.37 | 0.078 | Phosphodiesterase 7A inhibitor | 0.078 0.007 DBMET02633 0.059 0.024 DBMET02634 | DBMET02633 | |
| 0.017 | 0.375 | 0.086 | Protein kinase B gamma inhibitor | 0.086 0.042 DBMET02629 | DBMET02629 | |
| 0.018 | 0.378 | 0.055 | Potassium channel (Ca-activated) blocker | 0.055 0.052 DBMET02632 | DBMET02632 | |
| 0.02 | 0.385 | 0.144 | Lck kinase inhibitor | 0.144 0.069 DBMET02629 | DBMET02629 | |
| 0.005 | 0.373 | 0.034 | Histone deacetylase 4 inhibitor | 0.034 0.021 DBMET02631 | DBMET02631 | |
| 0.01 | 0.381 | 0.052 | CDK4/cyclin D inhibitor | 0.052 0.051 DBMET02634 | DBMET02634 | |
| 0.009 | 0.383 | 0.086 | Phosphodiesterase VII inhibitor | 0.086 0.021 DBMET02633 | DBMET02633 | |
| 0.006 | 0.384 | 0.019 | Antibiotic Tetracycline-like | 0.019 0.004 DBMET02629 0.018 0.005 DBMET02631 0.019 0.004 DBMET02633 0.018 0.005 DBMET02634 | DBMET02633 | |
| 0.019 | 0.4 | 0.165 | Hepatocyte growth factor antagonist | 0.165 0.018 DBMET02633 | DBMET02633 | |
| 0.017 | 0.402 | 0.134 | Protein-tyrosine kinase Lyn inhibitor | 0.134 0.075 DBMET02629 | DBMET02629 | |
| 0.023 | 0.415 | 0.115 | Telomerase inhibitor | 0.1 0.033 DBMET02632 0.115 0.028 DBMET02633 | DBMET02633 | |
| 0.028 | 0.43 | 0.281 | Tyrosine kinase inhibitor | 0.281 0.047 DBMET02629 0.148 0.09 DBMET02633 0.189 0.073 DBMET02634 | DBMET02629 | |
| 0.015 | 0.423 | 0.066 | Thrombin inhibitor | 0.066 0.06 DBMET02631 | DBMET02631 | |
| 0.004 | 0.413 | 0.048 | Histone deacetylase 10 inhibitor | 0.048 0.012 DBMET02631 | DBMET02631 | |
| 0.004 | 0.424 | 0.179 | Janus tyrosine kinase 1 inhibitor | 0.179 0.006 DBMET02629 0.077 0.03 DBMET02634 | DBMET02629 | |
| 0.02 | 0.445 | 0.091 | Polo-like kinase-2 inhibitor | 0.08 0.044 DBMET02629 0.075 0.048 DBMET02633 0.091 0.034 DBMET02634 | DBMET02634 | |
| 0.006 | 0.44 | 0.044 | Histone deacetylase 11 inhibitor | 0.044 0.016 DBMET02631 | DBMET02631 | |
| 0.006 | 0.44 | 0.044 | Histone deacetylase class IV inhibitor | 0.044 0.016 DBMET02631 | DBMET02631 | |
| 0.01 | 0.446 | 0.102 | Erythropoietin receptor agonist | 0.102 0.01 DBMET02630 | DBMET02630 | |
| 0.004 | 0.447 | 0.048 | Factor X inhibitor | 0.048 0.022 DBMET02631 | DBMET02631 | |
| 0.004 | 0.449 | 0.099 | Poly(ADP-ribose) polymerase 2 inhibitor | 0.099 0.005 DBMET02629 0.027 0.021 DBMET02631 0.028 0.02 DBMET02633 0.035 0.014 DBMET02634 | DBMET02629 | |
| 0.007 | 0.456 | 0.194 | Bruton tyrosine kinase inhibitor | 0.07 0.026 DBMET02629 0.194 0.005 DBMET02634 | DBMET02634 | |
| 0.009 | 0.487 | 0.026 | CC chemokine 8 receptor antagonist | 0.026 0.01 DBMET02631 | DBMET02631 | |
| 0.015 | 0.51 | 0.202 | AXL receptor tyrosine kinase inhibitor | 0.202 0.009 DBMET02633 | DBMET02633 | |
| 0.019 | 0.531 | 0.111 | Viral attachment inhibitor | 0.111 0.017 DBMET02631 | DBMET02631 | |
| 0.015 | 0.534 | 0.08 | Phosphodiesterase XI inhibitor | 0.08 0.059 DBMET02629 | DBMET02629 | |
| 0.015 | 0.534 | 0.08 | Phosphodiesterase 11A inhibitor | 0.08 0.059 DBMET02629 | DBMET02629 | |
| 0.008 | 0.534 | 0.058 | CC chemokine 5 receptor antagonist | 0.058 0.028 DBMET02631 | DBMET02631 | |
| 0.004 | 0.556 | 0.166 | Dopamine D4 agonist | 0.166 0.009 DBMET02631 | DBMET02631 | |
| 0.005 | 0.569 | 0.353 | Bromodomain-containing protein 4 inhibitor | 0.353 0.003 DBMET02634 | DBMET02634 | |
| 0.005 | 0.621 | 0.12 | Poly(ADP-ribose) polymerase inhibitor | 0.12 0.006 DBMET02629 0.054 0.02 DBMET02631 0.07 0.013 DBMET02634 | DBMET02629 | |
| 0.013 | 0.638 | 0.164 | Potassium channel blocker | 0.164 0.121 DBMET02629 | DBMET02629 | |
| 0.005 | 0.64 | 0.09 | Poly(ADP-ribose) polymerase 1 inhibitor | 0.09 0.008 DBMET02629 0.037 0.027 DBMET02631 0.052 0.016 DBMET02634 | DBMET02629 | |
| 0.014 | 0.654 | 0.151 | Cholinergic | 0.151 0.075 DBMET02632 | DBMET02632 | |
| 0.008 | 0.681 | 0.277 | Potassium channel (Voltage-sensitive) blocker | 0.188 0.104 DBMET02629 0.277 0.057 DBMET02634 | DBMET02634 | |
| 0.01 | 0.692 | 0.061 | 5 Hydroxytryptamine 1B agonist | 0.061 0.026 DBMET02634 | DBMET02634 | |
| 0.005 | 0.708 | 0.298 | HERG channel blocker | 0.152 0.129 DBMET02629 0.298 0.049 DBMET02634 | DBMET02634 | |
| 0.004 | 0.73 | 0.075 | Oxytocin antagonist | 0.075 0.013 DBMET02631 | DBMET02631 | |
| 0.006 | 0.744 | 0.13 | Acetylcholinesterase inhibitor | 0.13 0.069 DBMET02632 | DBMET02632 | |
| 0.004 | 0.777 | 0.049 | Melatonin 2 agonist | 0.049 0.011 DBMET02634 | DBMET02634 | |
| 0.005 | 0.78 | 0.117 | Butyrylcholinesterase inhibitor | 0.117 0.048 DBMET02632 0.082 0.08 DBMET02633 | DBMET02632 | Ext | Pa | Pi | Pmax | Activity | Other Results | ID Pa_max |